Document:

Exhibit 10.1

 

[****] Certain information in this exhibit has been omitted
pursuant to Item 601(b)(10)(iv) of Regulation S-K because it is both (i) not material and (ii) would likely cause competitive harm to
the registrant if publicly disclosed. 

 

 

PROTOYPE
MANUFACTURE AGREEMENT

This
agreement is made on the date fully signed below by and between Fluitron Inc., a Pennsylvania corporation having a principal place of
business at 30 Industrial Dr., Ivyland, PA 18974 (“FLUITRON”) and Eco Innovation Group, Inc., (“ECOIG”) a Nevada
corporation, having a principal place of business at 16525 Sherman Way, Suite C-1, Van Nuys, CA 91406. Together FLUITRON and ECOIG shall
be referred to as “Parties” and individually as “Party.”

1.
     Purpose 

ECOIG
hereby engages FLUITRON to manufacture a prototype (“PROTOTYPE”) of ECOIG’s exclusively licensed glycerin extraction
technology (“TECHNOLOGY”).

2.     Confidential
Information

a)
Confidential Information means information and physical material relating to the TECHNOLOGY and the PROTOTYPE and each Party’s
business, not generally known or available to the public, and information and any confidential information entrusted to a Party in confidence
by third parties. Confidential Information includes, without limitation: inventions, patent applications, technical data, trade secrets
(whether or not defined as "trade secrets" under the Uniform Trade Secrets Act of California), technology, know-how, show-how,
prototypes, schematics, research, product or service ideas or plans, white papers, software codes and designs, algorithms, developments,
laboratory notebooks, processes, formulas, techniques, mask works, engineering designs and drawings, hardware configuration information,
agreements with third parties, lists of, or information relating to, employees, customers and consultants of a Party (including, but
not limited to, the names, contact information, jobs, compensation, and expertise of such employees, customers and consultants), lists
of, or information relating to, suppliers and customers, price lists, pricing methodologies, cost data, market share data, marketing
plans, licenses, contract information, business plans, financial forecasts, historical financial data, budgets, or other technology or
business information disclosed by a Party (whether by oral, written, touring facilities, graphic or machine-readable format), which Confidential
Information is designated in writing to be confidential or proprietary, or if given orally, is confirmed in writing as having been disclosed
as confidential or proprietary, or which should be reasonably understood by the receiving Party as confidential or propriety information
of that Party.

b)
A receiving Party shall not use any Confidential Information disclosed to it by the disclosing Party for its own use or use by others,
or for any purpose other than to carry out discussions concerning, and the undertaking of, the Technology. A receiving Party shall not
disclose or permit disclosure of any Confidential Information of the disclosing Party to third parties or to personnel associated with
the receiving Party, other than directors, officers, employees, consultants and representatives of the receiving Party (the "Representatives")
who are required to have the information in order to carry out discussions regarding, and evaluations to further develop the Technology,
provided the Representatives each sign a non-disclosure agreement which ECOIG will provide upon request. The receiving Party shall take
reasonable measures to protect the secrecy of and avoid disclosure or use of Confidential Information of the disclosing Party in order
to prevent it from falling into the public domain or the possession of persons other than those persons authorized under this Agreement
to have any such information. Such measures shall include the degree of care that receiving Party utilizes to protect its own Confidential
Information of a similar nature. A receiving party shall promptly notify the disclosing Party of any actual or suspected misuse, misappropriation
or unauthorized disclosure of Confidential Information of the disclosing Party which may come to receiving Party's attention.

 

    	  

    	 

    

 

c)
Notwithstanding the above, information disclosed hereunder shall not be considered "Confidential Information" as defined herein
where a receiving Party can demonstrate with written documentation that such information:

(i)       was
in the public domain at the time it was disclosed or has entered the public domain through no fault of the receiving Party;

(ii)       was
known to the receiving party, without restriction, at the time of disclosure, as evidenced by documentation in existence at the time
of disclosure;

(iii)       becomes
known to the receiving Party, without restriction, from a source other than the disclosing Party without breach of this Agreement by
the receiving Party and otherwise not in violation of the disclosing Party's rights;

 

(iv)       is
disclosed with the prior written approval of the disclosing Party; or

 

(v)       is
disclosed pursuant to the order or requirement of a court, administrative agency, or other governmental body to the extent necessary
to comply with such order or requirement of a court, administrative agency or other governmental body, provided, however, that the receiving
Party shall provide prompt notice of such court order or requirement to the disclosing Party, to enable it to seek a protective order
or otherwise prevent or restrict such disclosure.

 

3.
Intellectual Property and Ownership

 

a)
FLUITRON acknowledges that ECOIG owns valid and subsisting intellectual property rights in the TECHNOLOGY upon which the prototype (“PROTOTYPE”)
is based. FLUITRON further acknowledges that it acquires no proprietary rights in the TECHNOLOGY or PROTOTYPE, and the TECHNOLOGY and
PROTOTYPE shall be the exclusive property of ECOIG. 

 

b)
FLUITRON shall retain the detailed fabrication drawings, manufacturing procedures and engineering design calculationsCopies of the assembly
and layout drawings, and maintenance and service information will be provided to ECOIG. 

 

c)
ECOIG shall own the PROTOTYPE and all its materials and components and may use, manufacture and have manufactured the PROTOTYPE by a
third party, at its sole discretion; and

 

    	  

    	 

    

 

 

d)
ECOIG shall own all intellectual property it develops or that is developed solely or jointly by FLUITRON with ECOIG which relates to
the TECHNOLOGY and/or the PROTOTYPE, subject to the information retained by FLUITRON in subsection b) above.However, FLUITRON shall have
the non-exclusive, royalty free right to use technology, including parts, that it develops alone or jointly with ECOIG, in construction
or repair of extraction equipment, for use outside the field of glycerin based extraction. No license is granted to FLUITRON or its customers
to make, use or sell technology which infringes any claim of a patent owned or licensed by ECOIG or Glytech, LLC. 

 

4.
Payment Requirements

 

a)
ECOIG shall make payments to FLUITRON as set forth in the Quotation dated April 23, 2021, (the “Quotation”) attached hereto
as Exhibit 1, and incorporated in its entirety by reference, subject to the provisions of Section 5 for Performance, and Section 7 for
Termination.

 

b)
Demitri Hopkins (“HOPKINS”) must approve the drawings and list of materials and components to be purchased by FLUITRON, or
supplied by FLUITRON, for assembly of the PROTOTYPE, before any materials and components are purchased by FLUITRON. All approved materials
and components must be ordered within five (5) business days of payment by ECOIG, as set forth in the Quotation (Exhibit 1).

 

c)
HOPKINS must be reasonably consulted during assembly of the PROTOTYPE and must approve the final assembled PROTOTYPE, prior to a Factory
Acceptance Test, established by HOPKINS and/or ECOIG. HOPKINS will visit FLUITRON at least once a month to assist with development of
the PROTOTYPE, starting ten (10) business days after the approved materials and components are received by FLUITRON. He will also be
available to assist by telephone and video conferencing with at least 48 hours prior notice.

 

d)
An operable PROTOTYPE must be completed and pass the Factory Acceptance Test within eighteen (18) weeks after all materials and components
are purchased. Extensions may be granted by ECOIG for documented occurrences requiring extension.

 

5.
Performance

 

a)
If the PROTOTYPE does not pass the Factory Acceptance Test and/or is not operable, under the parameters established by ECOIG, and FLUITRON,
based on the approved drawings, then FLUITRON agrees to perform labor, with ECOIG paying for any additional materials and components
needed, to render the PROTOTYPE operable and to obtain passage of the Factory Acceptance Test. ECOIG shall pay the documented, reasonable
labor costs for such additional labor only if the inability to operate and/or pass the Factory Acceptance Test is a documented result
of fault of design or operation caused by information supplied by ECOIG, and replied upon by FLUITRON. All labor pursuant to this subsection
shall be performed promptly and completed within a reasonable time not to exceed thirty (30) days.

 

b)
Factory Acceptance Test parameters and qualifying criteria shall be based on the mechanical operation of the PROTOTYPE, and not based
off any chemical or process achievement of successful extraction. Mechanical operation of the system will include target set points of
pressure, temperature, and flow, functionality of controls and safety interlocks, and the physical integrity of the system.

[This
is a “cure” provision and is not needed, because covered in a) above].

 

 

    	  

    	 

    

 

c)
At its option, if the PROTOTYPE fails to be operable or to pass the Factory Acceptance Test, ECOIG may obtain possession of the PROTOTYPE
and all of its associated materials and components. ECOIG may then proceed as it determines with the PROTOTYPE, including having it assembled
by a third party. If ECOIG obtains the PROTOTYPE pursuant to this subsection, FLUITRON shall no longer have to honor any warranties provided
pursuant to Section 6, below. 

 

 

6.
FLUITRON Warranty 

 

FLUITRON
warrants the PROTOTYPE as provided in its Warranty and Conditions document, attached hereto as Exhibit 2, and incorporated in its entirety
by reference.

 

7.
Term and Termination

 

a)
This Agreement shall be in effect until the end of any applicable warranty by FLUITRON after the design, assembly, and acceptance by
ECOIG of passage of a Factory Acceptance Test of the PROTOTYPE, under parameters established by HOPKINS and/or ECOIG;

 

b)
Upon the failure of either Party to comply with any provision of this Agreement, thirty (30) days after written notice of such failure,
the other Party may elect to terminate this Agreement if no cure has been made satisfactory to that Party; and

 

c)
Upon termination according to the preceding subpart b) of this section of the Agreement, the PROTOTYPE, in its then existing state of
completion, and/or all copies, designs molds, materials and components paid by ECOIG for design and construction of the PROTOTYPE shall
be immediately delivered to ECOIG, at the cost of the terminated Party. 

 

d)
If this Agreement is terminated prior to completion of a PROTOTYPE which passes the Factory Acceptance Test, ECOIG shall be refunded
that portion of payments made to FLUITRON which were not for components and materials for which ECOIG paid and are returned to ECOIG.

 

8.
Exclusive Manufacture and Marking

 

a)
FLUITRON agrees that:

 

(i)
it will not manufacture, distribute or deliver the PROTOTYPE for, or supply the PROTOTYPE to, any person, company or organization, except
ECOIG;

 

(ii)
it will not produce any items in excess of the single PROTOTYPE without written authorization by ECOIG; and

 

b)
the PROTOTYPE manufactured by FLUITRON shall without exception, bear any patent, copyright or trademark notice as stipulated by ECOIG,
accompanied by such other information or notice as may be prescribed by law, or as Licensee may instruct in writing.

 

 

    	  

    	 

    

 

9.
Return of Materials

A
receiving Party shall not make any copies or duplicates of any Confidential Information except as otherwise expressly authorized by the
disclosing Party. Any materials, including materials, components or documents that have been furnished by a disclosing Party to the receiving
Party in connection with the TECHNOLOGY, PROTOTYPE or a Party’s business or technology shall be promptly returned by the receiving
party (or, with the disclosing Party's consent, destroyed), accompanied by all copies of such documentation, at the written request of
the disclosing Party.

10.
No Co-Ownership

Nothing
contained in this Agreement shall be construed to constitute the Parties as partners, joint venturers, co-owners or otherwise as participants
in a joint or common undertaking.

 

11.
Remedies

Each
Party's obligations set forth in this Agreement are necessary and reasonable in order to protect the Party and its business. Due to the
unique nature of the TECHNOLOGY, the PROTOTYPE and the Parties’ Confidential Information, monetary damages may be inadequate to
compensate a Party for any breach by the other Party of its covenants and agreements set forth in this Agreement. Accordingly, the Parties
each agree and acknowledge that any such violation or threatened violation may cause irreparable injury to a disclosing Party and, in
addition to any other remedies that may be available, in law, in equity or otherwise, the disclosing Party shall be entitled to obtain
injunctive relief against the threatened breach of this Agreement or the continuation of any such breach by the receiving Party, without
the necessity of proving actual damages.

 

12.
Attorneys' Fees

If
any action at law or in equity is brought to enforce or interpret the provisions of this Agreement, the prevailing party shall be entitled
to recover from the unsuccessful party all costs, expenses and reasonable attorneys' fees incurred therein by the prevailing party.

 

13.
Miscellaneous

 

a)
Governing Law and Venue. The validity, interpretation, construction and performance of this Agreement, and all acts and transactions
pursuant hereto and the rights and obligations of the Parties hereto shall be governed, construed and interpreted in accordance with
the laws of the state of California or federal law in California federal courts, without giving effect to principles of conflicts of
law and disputes shall be heard in the state or federal courts of Los Angeles County, Los Angeles, California;

 

b)
Entire Agreement. This Agreement sets forth the entire agreement and understanding of the Parties relating to the subject matter
herein and supersedes all prior or contemporaneous discussions, understandings and agreements, whether oral or written, between them
relating to the subject matter hereof;

 

 

    	  

    	 

    

 

c)
Amendments and Waivers. No modification of or amendment to this Agreement, nor any waiver of any rights under this Agreement,
shall be effective unless in writing signed by the Parties to this Agreement. No delay or failure to require performance of any provision
of this Agreement shall constitute a waiver of that provision as to that or any other instance;

 

d)
Successors and Assigns. Except as otherwise provided in this Agreement, this Agreement, and the rights and obligations of the
Parties hereunder, will be binding upon and inure to the benefit of their respective successors, assigns, heirs, executors, administrators
and legal representatives. Neither Party may assign any of its rights and obligations under this Agreement with the prior written consent
of the other Party;

 

e)
Non-solicitation. Each Party agrees that for a period of three (3) years from the date of this Agreement, it shall not, directly
or indirectly, solicit, induce, recruit or encourage any of the other Party' s employees or consultants to terminate their business relationship
with the other Party, or take away such employees or consultants, or attempt to solicit, induce, recruit, encourage or take away employees
or consultants of the other Party, either for itself or for any other person or entity;

 

f)
Notices. Any notice, demand or request required or permitted to be given under this Agreement shall be in writing and shall be
deemed sufficient when delivered personally or by overnight courier or sent by email or facsimile, or 48 hours after being deposited
in the U.S. mail as certified or registered mail with postage prepaid, addressed to the Parties at the following addresses, or to such
other addresses as any party to this Agreement may specify by notice to the other parties:

 

If
to FLUITRON:

Mr.
Anthony Ciccarine, President

30
Industrial Dr, Ivyland, PA 18974

Telephone:
(215) 355-9970

Email:
info@fluitron.com

 

If
to ECOIG:

Ms.
Julia Otey-Raudes, CEO

Eco
Innovation Group, Inc.

16525
Sherman Way Suite C-1

Van
Nuys, CA 91406

Telephone:
(800) 922-4356

Mail:
julia.otey@ecoig.com

 

g)
Construction. This Agreement is the result of negotiations between, and has been reviewed by, each of the Parties hereto and their
respective counsel, if any. Accordingly , this Agreement shall be deemed to be the product of all of the Parties hereto, and no ambiguity
shall be construed in favor of or against any one of the Parties hereto;

 

h)
Counterparts. This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall
be deemed an original, and all of which together shall constitute one and the same agreement. Execution of a facsimile or scanned copy
will have the same force and effect as execution of an original, and a facsimile or scanned signature will be deemed an original and
valid signature; and

 

    	  

    	 

    

 

 

i)
Authority to Execute. Each person executing this Agreement on behalf of a corporation or other entity personally warrants and
guarantees that he or she has full authority to execute this Agreement on behalf of such corporation or entity and that this Agreement
is binding on the corporation or entity.

 

The
Parties intend for this Agreement to be effective as of the date fully signed below.

 

	Eco Innovation Group, Inc.	 
	 	 	 	 
	By:   	/s/ Julia Otey-Raudes	 	Date: May 19, 2021
	 	Julia Otey-Raudes	 	 
	 	Title:
Chief Executive Officer	 	 

 

 

 

	Fluitron
Inc.	 
	 	 	 	 
	By:   	/s/ Anthony
P. Ciccarine	 	Date: May 19, 2021
	 	Anthony
P. Ciccarine	 	 
	 	Title:
President	 	 

 

 

 

 

 

 

    	  

    	 

    

 

EXHIBIT
1

Fluitron,
Inc. 

30 Industrial Drive 
Ivyland, PA 18974 

Phone
(215) 355-9970 
 Fax (215) 355-9074 

E-mail:
info@fluitron.com

DATE:
April 23, 2021 

TO:
Eco Innovation Group, Inc. 

ATTN:
Patrick Laurie 

EMAIL:
Patrick.laurie@ecoig.com 

RE:
Fluitron Quotation No. Q21-2588, Rev. 2 

SENDER:
Ryan Malone 

PAGES:
 4 

 

Dear
Patrick:

Thank
you for your recent inquiry and your interest in Fluitron. We are pleased to provide a quotation on the equipment that you require. This
quote includes the design, fabrication, and factory acceptance test of the requested Glycerin extraction system. Fluitron understands
that this system will either ship out to you for you to perform your own extraction tests, or remain at Fluitron’s facility where
we could perform the extraction tests for an additional fee.

Our
quotation is subject to and in accordance with Fluitron, Inc.’s Terms and Conditions/Warranty.

We
trust that our information is complete and satisfactory. If you have any questions or comments, please don’t hesitate to contact
us.

Sincerely,

Ryan
Malone

Encl:
Terms and Conditions/Warranty

 

SKT-1648

SKT-1648-1

 

    	  

    	 

    

 

Price:
$307,200.00

Delivery:
5 – 6 weeks for approval drawings

17
– 18 weeks for equipment after drawing approval

Payment
Terms: Note: Credit references must be submitted and approved before order acceptance. 

Progress
Payments: (Due upon Receipt) 

20%
- With Order Placement

50%
- Prior to Purchasing of Materials & Components

20%
- Prior to Start of Assembly

10%
- After Completion of Factory Acceptance Test

Shipping
Terms: FOB Origin Freight Collect

Warranty:
See Attached

Validity
of Offer: 30 Days from date of quotation

Because
of the specialized nature of our business and our dependence on the supply of specialty materials and components, Fluitron cannot guarantee
delivery dates. The estimated delivery date shown on this quotation assumes that all raw materials and components as well as any required
drawings are received as expected.

 

 

 

    	  

    	 

    

 

System
Overview

This
extraction system will be designed and build in accordance with the basic operating scenario as shared by Eco Innovation Group, which
consists of ******* to perform an extraction and separation process through the lab scale vessels that we will be building for the system.
The full system schematic is attached to this quote and the main items in the system are detailed further in this offer. All items on
the system will be new items, except for the .. *******. Those excepted items will be provided by Fluitron on a temporary basis and will
eventually return to Fluitron after the prototype has served its purpose for testing and evaluation of the process. The basic physical
constraints and technical specifications of the system are:

Maximum
Pressure: 1200 psig

Maximum
Temperature: 800° F

*******

*******

Electrical
Supply: 230/460V 3ph 60Hz

Component
Specifications

Compressor

In
order to compressor the helium, Fluitron will be lending our high pressure, small capacity diaphragm compressor to the system. *******
While the compressor will not be controllable beyond simple on/off function, the upstream flow control valve will ensure it delivers
a consistent and controllable flow of gas.

A5-400
Metal Diaphragm Compressor

Make:
Fluitron

Inlet
Pressure: Atmospheric

Max
Discharge Pressure: 6000 psig

Motor:
2 HP

MOC:
SS (Wetted)

 

    	  

    	 

    

 

Extractor
& Separator

The
Extractor and Separator will share almost identical designs to reduce costs and lead time. Each one will be designed to handle the full
pressure and temperature of the system while providing a sufficient amount of volume for performing qualitative extraction tests.

Volume:
1L

Design:
1500 psig @ 800° F

ID:
2.47”

IL:
12.75”

MOC:
304/316 SS

Construction:
Welded Flanged Vessel w/ Metal Seal

*******

Diaphragm
Metering Pump

Discharge
Pressure: 1200 psig

Plunger
Diameter: 20 mm

MOC:
316 SS

Motor:
0.75 HP

Heaters

Due
to the high pressures and temperatures, both heaters will be of a similar design wherein a SS tube is encased in a solid block of metal
which is then heated externally using electric heaters. This method ensures that the heater can sufficiently withstand the pressure of
the system while still providing the necessary heat to the process stream effectively. The Pre-Heater will be cast in Aluminum while
the Heater will be cast in Bronze.

Construction:
Cast-in Process Heaters

Rating:
8kW (Pre-Heater) & 5kW (Heater)

MOC:
SS (Wetted)

Electrical:
480V 3ph 60Hz

Temperature
Rating: 500° F (Pre-Heater) & 800° F (Heater)

Controls

The
entire system will be controlled via a desktop PC provided by Fluitron with LabVIEW software installed on it. All operational logic is
performed by a LabVIEW program running on the computer. This software will communicate with the system, perform data acquisition, and
control various functions including the individual flowrates of both the ******* both heaters and safety interlocks. Because we are opting
to use a LabVIEW controller, the interface and data acquisition will be incredibly flexible and user friendly compared to more traditional
PLC systems. Included as a part of the controls package is a full Operation Logic Document write up which will detail the use and troubleshooting
of the controls.

 

    	  

    	 

    

 

 

 

EXHIBIT 2

 

TERMS AND CONDITIONS
/ WARRANTY

 

 

		a)	Fluitron warrants equipment of its manufacture for a period of one year from shipment date against defects in

material or workmanship, provided
that its installation, application and maintenance are within the design specifications. Normal wearing parts or other parts that have
a useful life of less than one year are excluded and would have a limited warranty. Fluitron products are designed and built to be used
under the direction of trained professionals in compliance with government and industrial safety standards. Handling of toxic, dangerous,
flammable or explosive substances with Fluitron products is at the user’s risk.

 

		b)	Components, not of our manufacture, are not covered by this warranty. The manufacturer’s warranty applies.

 

		c)	Because of the many variables of service conditions, no warranty of performance implied or otherwise, can be made on items of our
manufacture regarding wear to equipment caused by corrosion or abrasion of foreign objects, vibration, improper lubrication or failure
to provide proper inlet conditions or flow.

 

		d)	Fluitron will correct by repair or replacement, at our option and our expense, any proven defects subject to the above, provided immediate
written notice of such defects is given. Buyer is responsible for all shipping charges to Fluitron’s facility.

 

		e)	The warranty period will not be extended for items repaired under warranty. The complete warranty period is as stated in item (a)
above.

 

		f)	If returning the equipment for warranty repair in not possible, Fluitron can provide a Field Service Technician under the following
conditions:

 

		1.	Purchase order is required in advance of travel

		2.	If it is determined that the warranty claim is valid, the customer will be responsible for travel, lodging and living expenses only.

		3.	If it is determined that the warranty claim is not valid, customer will be responsible for both expenses and service fees according
to Fluitron’s current Field Service Rates.

 

		g)	When possible, Fluitron, at its discretion, may accept photographs provided by the customer to validate a warranty claim

 

		h)	The total financial obligation of Fluitron does not exceed the purchase price of the items of our manufacture. We will not assume
liability for repairs or replacement by others without our authorization. In no extent shall Fluitron be liable for consequential damages
including, but not limited to, damages for loss of use, loss of revenue or profits or loss of use or damage to property or equipment of
others.

 

		i)	Fluitron expressly disclaims all other express and/or implied warranties including warranties of merchantability and fitness for purpose.
In no event shall Fluitron be liable for any direct or indirect, incidental, special or consequential damages of any nature.

 

		j)	Fluitron expects to receive the net amount invoiced. If there are any taxes/duties or fees of any kind resulting from order fulfillment
or shipment, they must be paid by the purchaser.EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 

Microchip Technology Incorporated 

$1,000,000,000 0.983% Senior Secured Notes due 2024 

Purchase Agreement 
  

					
		  		  	May 18, 2021

 J.P. Morgan Securities LLC 

Truist Securities, Inc. 
 Wells Fargo Securities, LLC 

As Representatives of the 
   several Initial Purchasers
listed 
   in Schedule 1 hereto 
 c/o J.P. Morgan
Securities LLC 
 383 Madison Avenue 
 New York, New York 10179

 c/o Truist Securities, Inc. 
 3333 Peachtree Road NE 

Atlanta, Georgia 30326 
 c/o Wells Fargo Securities, LLC 

550 SouthTryon Street, 5th Floor 

Charlotte, North Carolina 28202 
 Ladies and Gentlemen: 

Microchip Technology Incorporated, a Delaware corporation (the “Company”), proposes to issue and sell to the several initial
purchasers listed in Schedule 1 hereto (the “Initial Purchasers”), for whom you are acting as representatives (the “Representatives”), $1,000,000,000 principal amount of its 0.983% Senior Secured Notes due 2024 (the
“Securities”). The Securities will be issued pursuant to an Indenture to be dated as of May 28, 2021 (the “Indenture”), among the Company, the guarantors listed in Schedule 2 hereto (the
“Guarantors”) and Wells Fargo Bank, National Association, as trustee (in such capacity, the “Trustee”) and as collateral agent (in such capacity, the “Collateral Agent”), and will be guaranteed in
accordance with the terms of the Indenture on a secured senior basis (the “Guarantees”) by each of the Guarantors. 

  
 1 

 The Securities and the Guarantees will be secured by a first-priority lien, subject to
Permitted Liens (as defined below) and the limitations and qualifications set forth in the Indenture and the Security Agreement (as defined below), on substantially all of the tangible and intangible assets of the Company and the Guarantors, now
owned or hereafter acquired by the Company and any Guarantor, that secure the Senior Credit Facilities (as defined in the Time of Sale Information and the Offering Memorandum) and the Company’s outstanding 4.333% Senior Secured Notes due 2023
(the “4.333% 2023 Notes”), 2.670% Senior Secured Notes due 2023 (the “2.670% 2023 Notes”) and 0.972% Senior Secured Notes due 2024 (the “2024 Notes” and, together with 4.333% 2023 Notes and the
2.670% 2023 Notes, the “Outstanding Senior Secured Notes”) on a first-priority basis (the “Collateral”). The Collateral shall be described in: (a) with respect to personal property that constitutes Collateral
(subject to clause (b) below), the Pledge and Security Agreement to be dated as of the Closing Date (as defined below) and entered into by the Company and the Guarantors, a form of which will be attached to the Indenture (the “Security
Agreement”), (b) with respect to U.S. registered or applied for intellectual property, and any exclusive licenses in same where the Company or a Guarantor is an exclusive licensee, that constitutes Collateral in the Security Agreement and
in the Trademark Security Agreement, the Patent Security Agreement and the Copyright Security Agreement, each to be dated as of the Closing Date and entered into by each of the Company and the Guarantors to the extent a party thereto, forms of which
will be attached to the form of the Security Agreement attached to the Indenture (the “Trademark Security Agreement,” “Patent Security Agreement” and “Copyright Security Agreement,” and,
collectively, the “Intellectual Property Security Agreements”), each to be delivered to the Trustee, granting a first-priority security interest in the Collateral, subject to Permitted Liens, in favor of the Collateral Agent for its
benefit and each holder of the Securities and the successors and assigns of the foregoing. The term “Collateral Documents,” as used herein, shall mean the Security Agreement and the Intellectual Property Security Agreements together
with any other filings, amendments, joinders, supplements and agreements required to create or perfect the security interests in the Collateral. The rights of the holders of the Securities with respect to the Collateral shall be further governed by
the First Lien Priority Intercreditor Agreement dated as of May 29, 2018 (as supplemented by Joinder No. 1, dated March 27, 2020, Joinder No. 2, dated May 29, 2020, and by Joinder No. 3, dated December 17, 2020,
and as may be further amended and supplemented, the “Intercreditor Agreement”), among the Company, the Guarantors, JPMorgan Chase Bank, N.A., as administrative agent, Wells Fargo Bank, National Association, as the notes collateral
agent, and each additional Authorized Representative from time to time party thereto, in connection with which the Collateral Agent will execute a joinder (the “Joinder to the Intercreditor Agreement”) to become a party thereto in
respect of the Securities and the Guarantees. 
 The Company expects to use the net proceeds from the offer and sale of the Securities,
together with borrowings under the Senior Credit Facilities, to repay the Company’s outstanding 3.922% Senior Secured Notes due 2021 (the “2021 Notes”) at maturity and to pay accrued and unpaid interest on the 2021 Notes and
all related fees and expenses of the offering. As of March 31, 2021, $1,000,000,000 aggregate principal amount of the Company’s 2021 Notes, which will mature on June 1, 2021, was outstanding. 

  
 2 

 The Company and the Guarantors hereby confirm their agreement with the several Initial
Purchasers concerning the purchase and resale of the Securities, as follows: 
 1. Offering Memorandum and Transaction Information.

 The Securities will be sold to the Initial Purchasers without being registered under the Securities Act of 1933, as amended (the
“Securities Act”), in reliance upon an exemption therefrom. The Company and the Guarantors have prepared a preliminary offering memorandum dated May 18, 2021 (the “Preliminary Offering Memorandum”) and will
prepare an offering memorandum dated the date hereof (the “Offering Memorandum”) setting forth or incorporating by reference information concerning the Company, the Guarantors and the Securities. Copies of the Preliminary Offering
Memorandum have been, and copies of the Offering Memorandum will be, delivered by the Company to the Initial Purchasers pursuant to the terms of this purchase agreement (this “Agreement”). The Company hereby confirms that it has
authorized the use of the Preliminary Offering Memorandum, the other Time of Sale Information (as defined below) and the Offering Memorandum in connection with the offering and resale of the Securities by the Initial Purchasers in the manner
contemplated by this Agreement. References herein to the Preliminary Offering Memorandum, the Time of Sale Information and the Offering Memorandum shall be deemed to refer to and include any document incorporated by reference therein and any
reference to “amend,” “amendment” or “supplement” with respect to the Preliminary Offering Memorandum or the Offering Memorandum shall be deemed to refer to and include any documents filed after such date and
incorporated by reference therein. Capitalized terms used but not defined herein shall have the meanings given to such terms in the Preliminary Offering Memorandum. 

At or prior to the time when sales of the Securities were first made (the “Time of Sale”), the Company had prepared the
following information (collectively, the “Time of Sale Information”): the Preliminary Offering Memorandum, as supplemented and amended by the written communications listed on Annex A hereto, including the pricing information set
forth in the Pricing Term Sheet on Annex B hereto incorporated by reference into Annex A. 
 2. Purchase and Resale of the
Securities. 
 (a) The Company agrees to issue and sell the Securities to the several Initial Purchasers as provided in this Agreement,
and each Initial Purchaser, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase from the Company the respective principal
amount of Securities set forth opposite such Initial Purchaser’s name in Schedule 1 hereto at a price equal to 99.70% of the principal amount thereof plus accrued interest, if any, from May 28, 2021 to the Closing Date. The Company will
not be obligated to deliver any of the Securities except upon payment for all the Securities to be purchased as provided herein. 

  
 3 

 (b) The Company understands that the Initial Purchasers intend to offer the Securities for
resale on the terms set forth in the Time of Sale Information. Each Initial Purchaser, severally and not jointly, represents, warrants and agrees that: 

(i) it is a qualified institutional buyer within the meaning of Rule 144A under the Securities Act (a “QIB”)
and an accredited investor within the meaning of Rule 501(a) of Regulation D under the Securities Act (“Regulation D”); 

(ii) it has not solicited offers for, or offered or sold, and will not solicit offers for, or offer or sell, the Securities by
means of any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act; and 

(iii) it has not solicited offers for, or offered or sold, and will not solicit offers for, or offer or sell, the Securities as
part of their initial offering except: 
 (A) to persons whom it reasonably believes to be QIBs in transactions pursuant to
Rule 144A under the Securities Act (“Rule 144A”) and in connection with each such sale, it has taken or will take reasonable steps to ensure that the purchaser of the Securities is aware that such sale is being made in reliance on
Rule 144A; or 
 (B) in connection with offers and sales of Securities outside the United States pursuant to Regulation S
under the Securities Act (“Regulation S”), in accordance with the restrictions set forth in Annex C hereto. 
 3. (a) Each Initial
Purchaser acknowledges and agrees that the Company and, for purposes of the “no registration” opinions to be delivered to the Initial Purchasers pursuant to Sections 7(f) and 7(g), counsel for the Company and counsel for the Initial
Purchasers, respectively, may rely upon the accuracy of the representations and warranties of the Initial Purchasers, and compliance by the Initial Purchasers with their agreements, contained in paragraph (b) of Section 2 (including Annex
C hereto), and each Initial Purchaser hereby consents to such reliance. 
 (b) The Company acknowledges and agrees that the Initial
Purchasers may offer and sell Securities to or through any affiliate of an Initial Purchaser and that any such affiliate may offer and sell Securities purchased by it to or through any Initial Purchaser. 

(c) Payment for and delivery of the Securities will be made at the offices of Simpson Thacher & Bartlett LLP at 10:00 A.M., New York
City time, on May 28, 2021, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree upon in writing. The time and date of such payment and
delivery is referred to herein as the “Closing Date.” 

  
 4 

 (d) Payment for the Securities shall be made by wire transfer in immediately available funds
to the account(s) specified by the Company to the Representatives against delivery to the nominee of The Depository Trust Company (“DTC”), for the account of the Initial Purchasers, of one or more global notes representing the
Securities (collectively, the “Global Note”), with any transfer taxes payable in connection with the sale of the Securities duly paid by the Company. The Global Note will be made available for inspection by the Representatives not
later than 1:00 P.M., New York City time, on the business day prior to the Closing Date. 
 (e) The Company and the Guarantors acknowledge
and agree that each Initial Purchaser is acting solely in the capacity of an arm’s length contractual counterparty to the Company and the Guarantors with respect to the offering of Securities contemplated hereby (including in connection with
determining the terms of the offering) and not as a financial advisor or a fiduciary to, or an agent of, the Company, the Guarantors or any other person. Additionally, neither the Representatives nor any other Initial Purchaser is advising the
Company, the Guarantors or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company and the Guarantors shall consult with their own advisors concerning such matters and shall be responsible
for making their own independent investigation and appraisal of the transactions contemplated hereby, and the Initial Purchasers shall have no responsibility or liability to the Company or the Guarantors with respect thereto. Any review by the
Representatives or any Initial Purchaser of the Company, the Guarantors, and the transactions contemplated hereby or other matters relating to such transactions will be performed solely for the benefit of the Representatives or such Initial
Purchaser, as the case may be, and shall not be on behalf of the Company, the Guarantors or any other person. 
 4. Representations and
Warranties of the Company and the Guarantors. As of the Time of Sale, each of the Company and the Guarantors jointly and severally represents and warrants to each Initial Purchaser that: 

(a) Preliminary Offering Memorandum, Time of Sale Information and Offering Memorandum. The Preliminary Offering Memorandum, as of its
date, did not, the Time of Sale Information, at the Time of Sale, did not, and at the Closing Date, will not, and the Offering Memorandum, in the form first used by the Initial Purchasers to confirm sales of the Securities and as of the Closing
Date, in each case including the documents incorporated by reference therein, will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the
circumstances under which they were made, not misleading; provided that the Company and the Guarantors make no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information
relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives expressly for use in the Preliminary Offering Memorandum, the Time of Sale Information or the Offering Memorandum, it being
understood and agreed that the only such information furnished by any Initial Purchaser consists of the information described as such in Section 8(b) of this Agreement. 

  
 5 

 (b) Additional Written Communications.    The Company and the
Guarantors (including their agents and representatives, other than the Initial Purchasers in their capacity as such) have not made, used, prepared, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to
any written communication that constitutes an offer to sell or solicitation of an offer to buy the Securities (each such communication by the Company and the Guarantors or their agents and representatives (other than a communication referred to in
clauses (i) and (ii) of this sentence) an “Issuer Written Communication”) other than (i) the Preliminary Offering Memorandum, (ii) the Offering Memorandum, (iii) the documents listed on Annex A hereto, including
a term sheet substantially in the form of Annex B hereto, which constitute part of the Time of Sale Information, and (iv) any electronic road show or other written communications approved in writing in advance by the Representatives, in each
case used in accordance with Section 5(c) of this Agreement. Each such Issuer Written Communication, when taken together with the Time of Sale Information at the Time of Sale, did not, and at the Closing Date will not, contain any untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided that the Company and the Guarantors make
no representation or warranty with respect to any statements or omissions made in each such Issuer Written Communication in reliance upon and in conformity with information relating to any Initial Purchaser furnished to the Company in writing by
such Initial Purchaser through the Representatives expressly for use in any Issuer Written Communication, it being understood and agreed that the only such information furnished by any Initial Purchaser consists of the information described as such
in Section 8(b) of this Agreement. 
 (c) Incorporated Documents. The documents of the Company incorporated by reference in each
of the Time of Sale Information and the Offering Memorandum, when filed by the Company with the Securities and Exchange Commission (the “Commission”), conformed or will conform, as the case may be, in all material respects to the
requirements of the Securities Exchange Act of 1934, as amended, and the rules and regulations of the Commission thereunder (collectively, the “Exchange Act”), and such documents did not and will not contain any untrue statement of
a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; provided, however that no
representation is made as to any statement or omission that shall have been superseded or modified in either (i) a document subsequently filed with the Commission prior to the Time of Sale and incorporated by reference in each of the Time of
Sale Information and the Offering Memorandum or (ii) each of the Time of Sale Information and the Offering Memorandum. 
 (d)
Financial Statements. (i) The financial statements and the related notes thereto of the Company and its consolidated subsidiaries included or incorporated by reference in each of the Time of Sale Information and the Offering Memorandum
present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified; such
financial statements have been prepared in conformity with generally accepted accounting principles in the United States (“GAAP”) applied on a consistent basis throughout the periods covered thereby; and the

  
 6 

 
other financial information included or incorporated by reference in each of the Time of Sale Information and the Offering Memorandum with respect to the Company and its consolidated subsidiaries
has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown thereby. The interactive data in eXtensible Business Reporting Language included or
incorporated by reference in each of the Preliminary Offering Memorandum, the Time of Sale Information and the Offering Memorandum with respect to the Company and its consolidated subsidiaries fairly presents the information called for in all
material respects and is prepared in accordance with the Commission’s rules and guidelines applicable thereto. 
 (e) No Material
Adverse Change. Except as disclosed in each of the Time of Sale Information and the Offering Memorandum, since the date of the most recent financial statements of the Company included or incorporated by reference in each of the Time of Sale
Information and the Offering Memorandum (i) there has not been any material change in the capital stock (other than the issuance of shares of Common Stock, options to purchase or acquire shares of Common Stock or restricted stock units, in each
case granted under the Company’s currently existing equity incentive plans, as disclosed in the Time of Sale Information, or the issuance of Common Stock upon the exercise of outstanding options and warrants, the vesting of restricted stock
units or upon settlement of the Company’s outstanding 2.250% junior subordinated convertible debentures due 2037, its 1.625% convertible senior subordinated notes due 2025, its 1.625% convertible senior subordinated notes due 2027 or its 0.125%
convertible senior subordinated notes due 2024), long-term debt (other than any borrowings under the Senior Credit Facilities described in the Time of Sale Information and Offering Memorandum), notes payable or current portion of long term debt of
the Company or any of its subsidiaries, or any dividend or distribution of any kind declared (other than any regular quarterly cash dividend publicly declared by the Company prior to the date of this Agreement), set aside for payment, paid or made
by the Company on any class of capital stock, or any material adverse change, or any development involving a prospective material adverse change, in or affecting the business, properties, management, financial position or results of operations of
the Company and its subsidiaries taken as a whole; (ii) neither the Company nor any of its subsidiaries has entered into any transaction or agreement that is material to the Company and its subsidiaries taken as a whole or incurred any
liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii) neither the Company nor any of its subsidiaries has sustained any material loss or interference with its business
from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court or arbitrator or governmental or regulatory authority. 

(f) Organization and Good Standing. The Company and each of the Guarantors have been duly organized and are validly existing and in good
standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of property or the conduct of their respective
businesses as currently conducted requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they currently are engaged, except where the failure to be so
qualified or in good standing or have such power or 

  
 7 

 
authority would not, individually or in the aggregate, have or reasonably be expected to have a material adverse effect on the business, properties, management, financial position,
stockholders’ equity or results of operations of the Company and its subsidiaries, taken as a whole, or on the performance by the Company and the Guarantors of their respective obligations under the Transaction Documents (as defined below) (a
“Material Adverse Effect”). There are no corporations, associations or other entities required to be listed in Exhibit 21.1 to the Company’s annual report on Form 10-K for the fiscal year
ended March 31, 2021 other than the entities listed therein. The only subsidiaries that are “significant subsidiaries” of the Company within the meaning of Rule 1-02(w) of Regulation S-X of the Securities Act are set forth on Annex C hereof (a “Significant Subsidiary,” and together the “Significant Subsidiaries”). 

(g) Capitalization. The Company has, after giving effect to the offer and sale of the Securities and the use of proceeds therefrom, will
have, the capitalization as set forth in each of the Time of Sale Information and the Offering Memorandum under the heading “Capitalization”; and all the outstanding shares of capital stock or other equity interests of each subsidiary of
the Company has been duly and validly authorized and issued, is fully paid and non-assessable (except, (i) in the case of any foreign subsidiary of the Company, for directors’ qualifying shares and
(ii) as otherwise described in each of the Time of Sale Information and the Offering Memorandum) and are owned directly or indirectly by the Company, free and clear of any lien, charge, encumbrance, security interest, adverse ownership
interest, restriction on voting or transfer or any other claim of any third party (collectively, “Liens”), except for Liens securing obligations under the Senior Credit Facilities, the Outstanding Senior Secured Notes and the
Securities, each as described in each of the Time of Sale Information and the Offering Memorandum. 
 (h) Due Authorization. The
Company and each of the Guarantors have full right, power and authority to execute and deliver this Agreement, the Securities, the Indenture (including each Guarantee set forth therein), each of the Collateral Documents to the extent a party thereto
and the Intercreditor Agreement (collectively, the “Transaction Documents”), including granting the Liens and security interests to be granted by it pursuant to the Indenture and the Collateral Documents and to perform their
respective obligations hereunder and under the Transaction Documents; and all action required to be taken by the Company and each of the Guarantors for the due and proper authorization, execution and delivery of each of the Transaction Documents to
which they are a party and the consummation of the transactions contemplated thereby or by the Time of Sale Information and the Offering Memorandum have been duly and validly taken. 

(i) The Indenture. The Indenture has been duly authorized by the Company and each of the Guarantors and on the Closing Date will be duly
executed and delivered by the Company and each of the Guarantors and, when duly executed and delivered in accordance with its terms by each of the parties thereto, will constitute a valid and legally binding agreement of the Company and each of the
Guarantors enforceable against the Company and each of the Guarantors in accordance with its terms, except as enforceability may be limited by applicable bankruptcy, insolvency, fraudulent conveyance,
re-organization, moratorium or similar laws affecting the enforcement of creditors’ rights generally or by equitable principles relating to enforceability, including principles of commercial
reasonableness, good faith and fair dealing (regardless of whether enforcement is sought in a proceeding at law or equity) (collectively, the “Enforceability Exceptions”). 

  
 8 

 (j) The Securities and the Guarantees. The Securities have been duly authorized by
the Company and, when duly executed, authenticated, issued and delivered as provided in the Indenture and paid for as provided herein, will be duly and validly issued and outstanding and will constitute valid and legally binding obligations of the
Company enforceable against the Company in accordance with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture; and the Guarantees have been duly authorized by each of the Guarantors and, when
the Guarantees of the Guarantors have been duly executed, authenticated, issued and delivered as provided in the Indenture and paid for as provided herein, will be valid and legally binding obligations of each of the Guarantors, enforceable against
each of the Guarantors in accordance with their terms, subject to the Enforceability Exceptions, and will be entitled to the benefits of the Indenture. 

(k) Purchase Agreement. This Agreement has been duly authorized, executed and delivered by the Company and each of the Guarantors. 

(l) [Reserved] 
 (m) Collateral
Documents and Joinder to Intercreditor Agreement. As of the Closing Date, each of the Collateral Documents and the Joinder to the Intercreditor Agreement will have been duly authorized by the Company and each of the Guarantors, to the extent a
party thereto, and, when duly executed and delivered in accordance with its terms by each of the parties thereto, each of the Collateral Documents and the Intercreditor Agreement, as amended, modified and supplemented by the Joinder to the
Intercreditor Agreement, will constitute a valid and legally binding agreement of the Company and each of the Guarantors, to the extent a party thereto, enforceable against the Company and each of the Guarantors, to the extent a party thereto, in
accordance with its terms, subject to the Enforceability Exceptions. 
 (n) Descriptions of the Transaction Documents; Collateral.
Each Transaction Document conforms in all material respects to the description thereof contained in each of the Time of Sale Information and the Offering Memorandum. The Collateral conforms in all material respects to the description thereof
contained in each of the Time of Sale Information and the Offering Memorandum. 
 (o) Collateral Documents, Financing Statements and
Collateral. 
  

	 	(i)	 Upon execution and delivery, the Security Agreement and each of the Intellectual Property Security Agreements
will be effective to grant a legal, valid and enforceable security interest in all of the grantor’s right, title and interest in the Collateral described in such agreement, subject to the Enforceability Exceptions; 

  
 9 

	 	(ii)	 Upon due and timely filing and/or recording of properly completed financing statements and Intellectual
Property Security Agreements, as applicable, with respect to the Collateral, the security interests granted thereby will constitute valid, perfected first-priority liens and security interests in the Collateral described therein, to the extent such
security interests can be perfected by the filing and/or recording, as applicable, of such financing statements and Intellectual Property Security Agreements in favor of the Collateral Agent for the benefit of itself, the Trustee and the holders of
the Securities, and such security interests will be enforceable in accordance with the terms contained in the Collateral Documents and the Intercreditor Agreement against all creditors of the Company and the Guarantors, and subject only to liens
expressly permitted to be incurred or exist on the Collateral under the Indenture (“Permitted Liens”) and subject to the Enforceability Exceptions; and 

 

	 	(iii)	 The Company and the Guarantors collectively own, have rights in or have the power and authority to grant
security interests in the Collateral, free and clear of any liens other than the Permitted Liens. 

 (p) No Violation or
Default. None of the Company, the Guarantors or any of the Company’s significant subsidiaries set forth on Schedule 3 (the “Significant Subsidiaries”) is (i) in violation of its charter or by-laws or similar organizational documents; (ii) in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default, in the due performance or observance of any
term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement, lease or other agreement or instrument to which the Company, the Guarantors or any of the Company’s Significant Subsidiaries is a party or by which
the Company, the Guarantors or any of the Company’s Significant Subsidiaries is bound or to which any property or asset of the Company, the Guarantors or any of the Company’s Significant Subsidiaries is subject; or (iii) in violation
of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii) and (iii) above, for any such default or violation that would not,
individually or in the aggregate, have a Material Adverse Effect. 
 (q) No Conflicts. The execution, delivery and performance by the
Company and each of the Guarantors of each of the Transaction Documents to which each is a party (including, but not limited to, the filing of any applicable financing statements pursuant to the Security Agreement or the filing of the Intellectual
Property Security Agreements), the issuance and sale of the Securities and the issuance of the Guarantees, the grant and perfection of liens and security interests in the Collateral pursuant to the Security Agreement and the Intellectual Property
Security Agreements and compliance by the Company and each of the Guarantors with the terms thereof and the consummation of the transactions contemplated by the Transaction Documents or the Time of Sale Information and the Offering Memorandum will
not (i) after giving effect to the use of proceeds of the Notes, conflict with or result in a breach or violation of any of the terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of,
or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or any of its subsidiaries pursuant to, any indenture, 

  
 10 

 
mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or
to which any property, right or asset of the Company or any of its subsidiaries is subject (other than any lien or encumbrance created or imposed pursuant to the Collateral Documents), (ii) result in any violation of the provisions of the charter or
by-laws or similar organizational documents of the Company, the Guarantors or any of the Company’s Significant Subsidiaries or (iii) result in the violation of any law or statute or any judgment,
order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i) and (iii) of this sentence, for any such conflict, breach, violation, default, lien, charge or encumbrance that
would not, individually or in the aggregate, have a Material Adverse Effect. 
 (r) No Consents Required. No consent, approval,
authorization, order, registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company and each of the Guarantors of each of the
Transaction Documents to which each is a party, the issuance and sale of the Securities and the issuance of the Guarantees, the grant and perfection of liens and security interests in the Collateral pursuant to the Security Agreement and the
Intellectual Property Security Agreements and compliance by the Company and each of the Guarantors with the terms thereof and the consummation of the transactions contemplated by the Transaction Documents or the Time of Sale Information and the
Offering Memorandum, except (i) for any consents, approvals, authorizations, orders, registrations or qualifications as have been obtained, (ii) for such consents, approvals, authorizations, orders and registrations or qualifications as
may be required under applicable state securities laws in connection with the purchase and resale of the Securities by the Initial Purchasers, (iii) for such registrations and filings, including without limitation financing statements, as are
necessary or advisable to perfect the security interests granted pursuant to the Security Agreement and the Intellectual Property Security Agreements, and (iv) as otherwise contemplated by the Transaction Documents. 

(s) Legal Proceedings. Except as described in each of the Time of Sale Information and the Offering Memorandum, there are no legal,
governmental or regulatory investigations, actions, suits, or (“Actions”) proceedings pending to which the Company or any of its subsidiaries is or may be a party or to which any property of the Company or any of its subsidiaries is
or may be the subject that, individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect; and, except as described in each of the Time of Sale Information and the Offering Memorandum, to the knowledge of the
Company, no such Actions are threatened or, to the knowledge of the Company and each of the Guarantors, contemplated by any governmental or regulatory authority or threatened by others. 

(t) Independent Accountants. Ernst & Young LLP, who have certified certain financial statements of the Company and its
subsidiaries is an independent registered public accounting firm with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States)
and as required by the Securities Act. 

  
 11 

 (u) Title to Real and Personal Property. The Company and its subsidiaries have good
and valid title in fee simple to, or have valid rights to lease or otherwise use, all items of real and personal property that are described in or referred to in the Collateral Documents and all other real and personal property that are material to
the respective businesses of the Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i) do not materially interfere with the use made and
proposed to be made of such property by the Company and its subsidiaries, (ii) constitute Permitted Liens or (iii) could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. 

(v) Intellectual Property. (i) (a) The Company and its subsidiaries own or possess or can obtain on commercially reasonable terms
sufficient rights to all patents, patent applications, inventions, trademarks, service marks, trade names, trademark registrations, service mark registrations, domain names and other source indicators, copyrights and copyrightable works, licenses, know-how (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information, systems or procedures) (collectively, “Intellectual Property”) used in their
respective businesses as described in the Time of Sale Information and the Offering Memorandum, except for those the lack of which has not, individually or in the aggregate, had a Material Adverse Effect; (b) the conduct of the Company and its
subsidiaries’ businesses as described in the Time of Sale Information and the Offering Memorandum does not infringe, misappropriate, or otherwise violate any Intellectual Property of any person; (c) the Company and its subsidiaries have
not received any written notice of any claim of infringement or conflict with any Intellectual Property rights of others, except for those claims that do not materially interfere with the use of or proposed use of such Intellectual Property by the
Company and its subsidiaries or that have not had, individually or in the aggregate, a Material Adverse Effect; and (d) to the knowledge of the Company, the Intellectual Property owned by the Company and its subsidiaries is not being infringed,
misappropriated or otherwise violated by any person, except those with respect to clauses (b) and (d) such infringements, misappropriations or violations that do not materially interfere with the use of or proposed use of such Intellectual
Property by the Company and its subsidiaries or that have not had, individually or in the aggregate, a Material Adverse Effect. 
 (ii) The
Company and its subsidiaries have taken commercially reasonable actions to protect (a) all personal information collected, stored, used, shared, processed or disposed of by or on behalf of them (“Personal Data”), and
(b) the integrity, operation and security of all computers, software, websites, applications, databases, networks, and other information technology assets used by the Company and its subsidiaries in their respective businesses (collectively,
“IT Assets”), and the Personal Data or any other confidential information within such IT Assets, except where the failure to take such commercially reasonable actions would not have, individually or in the aggregate, a Material
Adverse Effect. To the knowledge of the Company, there have been no breaches of, or unauthorized use of or access to, any IT Assets or Personal Data, except for any that have not resulted in material liability to the Company and its subsidiaries,
taken as a whole. 

  
 12 

 (iii) The Company and its subsidiaries are in compliance with all applicable federal, state,
local and foreign laws, rules and regulations, requirements, decisions and orders relating to (x) any Intellectual Property owned by the Company or any of its subsidiaries, (y) the privacy and security of any Personal Data, and
(z) the security of IT Assets used in their respective businesses (and the data therein) except in the case of (x), (y), or (z), where such non-compliance would not have, individually or in the aggregate,
a Material Adverse Effect. 
 (w) No Undisclosed Relationships.    No relationship, direct or indirect, exists
between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, other affiliates of the Company or any of its subsidiaries, on the other, that would be required by the Securities Act to be
described in a registration statement on Form S-1 to be filed with the Commission and that is not so described in each of the Time of Sale Information and the Offering Memorandum. 

(x) Investment Company Act. The Company and each of the Guarantors is not, and after giving effect to the offering and sale of the
Securities and the application of the proceeds thereof as described in each of the Time of Sale Information and the Offering Memorandum will not be, required to register as an investment company or an entity “controlled” by an
“investment company,” in each case as defined under the Investment Company Act of 1940, as amended. 
 (y) Taxes. The
Company and its subsidiaries have paid all federal, state, local and foreign taxes and filed all tax returns required to be paid or filed through the date hereof; and except as otherwise disclosed in each of the Time of Sale Information and the
Offering Memorandum, there is no tax deficiency that has been, or could reasonably be expected to be, asserted against the Company or any of its subsidiaries or any of their respective properties or assets except, in each case, for (i) any such
taxes or tax deficiencies that are currently being contested in good faith and for which the Company has established adequate reserves or (ii) as would not, individually or in the aggregate, have a Material Adverse Effect. 

(z) Licenses and Permits. The Company and its subsidiaries possess all licenses, sub-licenses,
certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their
respective properties or the conduct of their respective businesses as described in each of the Time of Sale Information and the Offering Memorandum, except where the failure to possess or make the same would not, individually or in the aggregate,
have a Material Adverse Effect; and except as described in each of the Time of Sale Information and the Offering Memorandum, neither the Company nor any of its subsidiaries has received notice of any revocation or modification of any such license, sub-license, certificate, permit or authorization or has any reason to believe that any such license, sub-license, certificate, permit or authorization will not be renewed in
the ordinary course, except where such revocation, modification or non-renewal would not, individually or in the aggregate, have a Material Adverse Effect. 

(aa) No Labor Disputes. No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the
knowledge of the Company and each of the Guarantors, is contemplated or threatened and neither the Company nor any Guarantor is aware of any existing or imminent labor disturbance by, or dispute with, the employees of any of the Company’s or
any of the Company’s subsidiaries’ principal suppliers, contractors or customers, except as would not have a Material Adverse Effect. 

  
 13 

 (bb) Certain Environmental Matters. (i) To the knowledge of the Company, the
Company and its subsidiaries (x) are in compliance with any and all applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees, and orders relating to the protection of human health or
safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, “Environmental Laws”); (y) have received and are in compliance with all permits, licenses, certificates
or other authorizations or approvals required of them under applicable Environmental Laws to conduct their respective businesses; and (z) have not received notice of any actual or potential liability under or relating to any Environmental Laws,
including for the investigation or remediation of any disposal or release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such
notice, and (ii) there are no costs or liabilities associated with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i) and (ii) above, for any such failure to comply, or failure to
receive required permits, licenses or approvals, or cost or liability, as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii) except as described in each of the Time of Sale
Information and the Offering Memorandum, the Company and its subsidiaries are not aware of any issues regarding compliance with Environmental Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic
substances or wastes, pollutants or contaminants, that could reasonably be expected to have a Material Adverse Effect. 
 (cc) Compliance
with ERISA. (i) Each employee benefit plan, within the meaning of Section 3(3) of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), for which the Company or any member of its “Controlled
Group” (defined as any entity, whether or not incorporated, that is under common control with the Company within the meaning of Section 4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under
Section 414(b)(c)(m) or (o) of the Internal Revenue Code of 1986, as amended (the “Code”)) would have any liability (each, a “Plan”) has been maintained in compliance with its terms and the requirements of
any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code, except as would not, individually or in the aggregate, have a Material Adverse Effect; (ii) no prohibited transaction, within the meaning
of Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption, except as would not, individually or in the aggregate, have a
Material Adverse Effect; (iii) for each Plan that is subject to the funding rules of Section 412 of the Code or Section 302 of ERISA, the minimum funding standard of Section 412 of the Code or Section 302 of ERISA, as
applicable, has been satisfied (without taking into account any waiver thereof or extension of any amortization period) and is reasonably expected to be satisfied in the future (without taking into account any waiver thereof or extension of any
amortization period); (iv) the fair market value of the assets of each Plan exceeds the present value of all benefits accrued under such Plan (determined based on those assumptions used to fund 

  
 14 

 
such Plan), except as would not, individually or in the aggregate, have a Material Adverse Effect; (v) no “reportable event” (within the meaning of Section 4043(c) of ERISA
and the regulations promulgated thereunder) has occurred or is reasonably expected to occur; (vi) neither the Company nor any member of the Controlled Group has incurred any liability under Title IV of ERISA (other than contributions to the
Plan or premiums to the Pension Benefit Guaranty Corporation, in the ordinary course and without default) in respect of a Plan (including a “multiemployer plan”, within the meaning of Section 4001(a)(3) of ERISA); and (vii) there
is no pending audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation or any other governmental agency or any foreign regulatory agency with respect to any Plan, except as would
not, individually or in the aggregate, have a Material Adverse Effect. 
 (dd) Disclosure Controls. The Company maintains an effective
system of “disclosure controls and procedures” (as defined in Rule 13a-15(e) of the Exchange Act) that is applicable to the Company and its subsidiaries that is designed to ensure that information
required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the Commission’s rules and forms, including controls and
procedures designed to ensure that such information is accumulated and communicated to the Company’s executive officers as appropriate to allow timely decisions regarding required disclosure. The Company and its subsidiaries have carried out
evaluations of the effectiveness of their disclosure controls and procedures as required by Rule 13a-15 of the Exchange Act. 

(ee) Accounting Controls. The Company and its subsidiaries maintain systems of “internal control over financial reporting” (as
defined in Rule 13a-15(f) of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under the supervision of, their respective principal executive officers and
principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with GAAP. The
Company maintains internal accounting controls sufficient to provide reasonable assurance that (i) transactions are executed in accordance with management’s general or specific authorizations; (ii) transactions are recorded as
necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii) access to assets is permitted only in accordance with management’s general or specific authorization; and
(iv) the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences. Except as disclosed in each of the Time of Sale Information and the
Offering Memorandum, (A) there are no material weaknesses in the Company’s internal controls and (B) the Company’s auditors and the Audit Committee of the Board of Directors of the Company have been advised of any fraud, whether
or not material, that involves management or other employees who have a significant role in the Company’s internal controls over financial reporting. 

  
 15 

 (ff) No Unlawful Payments. Neither the Company nor any of its subsidiaries, nor any
director or officer of the Company or any of its subsidiaries nor, to the knowledge of the Company and each of the Guarantors, any employee, agent, affiliate or other person associated with or acting on behalf of the Company or any of its
subsidiaries has (i) used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii) made or taken an act in furtherance of an offer, promise or authorization of
any direct or indirect unlawful payment or unlawful benefit to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an
official capacity for or on behalf of any of the foregoing, or any political party or party official or candidate for political office; (iii) violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977, as amended,
or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other
applicable anti-bribery or anti-corruption law; or (iv) made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment,
kickback or other unlawful or improper payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce, policies and procedures designed to promote and ensure compliance in all
material respects with all applicable anti-bribery and anti-corruption laws. 
 (gg) Insurance. Except as disclosed in the Time of
Sale Information and the Offering Memorandum, the Company and its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption insurance, which insurance is in amounts and
insures against such losses and risks as are expected to be adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i) received notice from any insurer or
agent of such insurer that material capital improvements or other material expenditures are required or necessary to be made in order to continue such insurance or (ii) any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be necessary to continue its business. 

(hh) Compliance with Anti-Money Laundering Laws. The operations of the Company and its subsidiaries are and have been conducted in
compliance in all material respects with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the applicable money laundering statutes of all
jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines, issued, administered or enforced by any governmental agency
(collectively, the “Anti-Money Laundering Laws”), and no action, suit or proceeding by or before any court or governmental agency, authority or body or any arbitrator involving the Company or any of its subsidiaries with respect to
the Anti-Money Laundering Laws is pending or, to the knowledge of the Company or any of the Guarantors, threatened. 
 (ii) No Conflicts
with Sanctions Laws. Neither the Company nor any of its subsidiaries, directors or officers, nor, to the knowledge of the Company or any of the Guarantors, any employee, agent, affiliate or other person associated with or acting on behalf of the
Company or any of its subsidiaries is currently the subject or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, 

  
 16 

 
the Office of Foreign Assets Control of the U.S. Department of the Treasury (“OFAC”) or the U.S. Department of State and including, without limitation, the designation as a
“specially designated national” or “blocked person”), the United Nations Security Council (“UNSC”), the European Union, Her Majesty’s Treasury (“HMT”), or other relevant sanctions authority
(collectively, “Sanctions”), nor is the Company, any of its subsidiaries or any of the Guarantors located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation,
Cuba, Iran, North Korea, Syria and Crimea (each, a “Sanctioned Country”); and the Company will apply the net proceeds from the sale of the Securities as described in the Time of Sale Information and the Offering Memorandum under the
heading “Use of proceeds” and will not directly or knowingly indirectly use the proceeds of the offering of the Securities hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or
other person or entity (i) to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation, is the subject or target of Sanctions, (ii) to fund or facilitate any activities of or
business in any Sanctioned Country or (iii) in any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter, initial purchaser, advisor, investor or otherwise) of
Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in, are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or
the target of Sanctions or with any Sanctioned Country. 
 (jj) Senior Indebtedness. The Securities constitute “senior
indebtedness” as such term is defined in any indenture or agreement governing any outstanding subordinated indebtedness of the Company. 

(kk) No Restrictions on Subsidiaries. Except as disclosed in the Time of Sale Information and the Offering Memorandum, no subsidiary of
the Company is currently prohibited, directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary’s capital
stock or similar ownership interest, from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary’s properties or assets to the Company or any other subsidiary of the
Company, except for any such restrictions (a) contained in the Senior Credit Facilities, or (b) that will be permitted by the Indenture. 

(ll) No Broker’s Fees. Except as disclosed in the Time of Sale Information and the Offering Memorandum, none of the Company or any
of its subsidiaries is a party to any contract, agreement or understanding with any person (other than the Transaction Documents) that would give rise to a valid claim against any of them or any Initial Purchaser for a brokerage commission,
finder’s fee or like payment in connection with the offering and sale of the Securities. 
 (mm) Rule 144A Eligibility. On the
Closing Date, the Securities will not be of the same class as securities listed on a national securities exchange registered under Section 6 of the Exchange Act or quoted in an automated inter-dealer quotation system; and each of the
Preliminary Offering Memorandum and the Offering Memorandum, as of its respective date, contains or will contain all the information that, if requested by a prospective purchaser of the Securities, would be required to be provided to such
prospective purchaser pursuant to Rule 144A(d)(4) under the Securities Act. 

  
 17 

 (nn) No Integration. None of the Company or any of its affiliates (as defined in Rule
501(b) of Regulation D) has, directly or through any agent, sold, offered for sale, solicited offers to buy or otherwise negotiated in respect of, any security (as defined in the Securities Act), that is or will be integrated with the sale of the
Securities in a manner that would require registration of the Securities under the Securities Act. 
 (oo) No General Solicitation or
Directed Selling Efforts. None of the Company or any of its affiliates or any other person acting on its or their behalf (other than the Initial Purchasers or persons acting on their behalf, as to which no representation is made) has
(i) solicited offers for, or offered or sold, the Securities by means of any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning
of Section 4(a)(2) of the Securities Act or (ii) engaged in any directed selling efforts within the meaning of Regulation S under the Securities Act (“Regulation S”), and all such persons have complied with the offering
restrictions requirement of Regulation S. 
 (pp) Securities Law Exemptions. Assuming the accuracy of the representations and
warranties of the Initial Purchasers contained in Section 2(b) (including Annex C hereto) and their compliance with their agreements set forth therein, it is not necessary, in connection with the issuance and sale of the Securities to the
Initial Purchasers and the offer, resale and delivery of the Securities by the Initial Purchasers in the manner contemplated by this Agreement, the Time of Sale Information and the Offering Memorandum, to register the Securities under the Securities
Act or to qualify the Indenture under the Trust Indenture Act of 1939, as amended. 
 (qq) No Stabilization. None of the Company or
any of the Guarantors has taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. 

(rr) Margin Rules. Neither the issuance, sale and delivery of the Securities nor the application of the proceeds thereof by the Company
as described in each of the Time of Sale Information and the Offering Memorandum will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any other regulation of such Board of Governors. 

(ss) Forward-Looking Statements. No forward-looking statement (within the meaning of Section 27A of the Securities Act and
Section 21E of the Exchange Act) included or incorporated by reference in any of the Time of Sale Information or the Offering Memorandum has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith. 

(tt) Statistical and Market Data. Nothing has come to the attention of the Company or any Guarantor that has caused the Company or such
Guarantor to believe that the statistical and market-related data included or incorporated by reference in each of the Time of Sale Information and the Offering Memorandum is not based on or derived from sources that are reliable and accurate in all
material respects. 

  
 18 

 (uu) Sarbanes-Oxley Act. There is and has been no failure on the part of the Company
or, to the Company’s knowledge, any of the Company’s directors or officers, in their capacities as such, to comply in all material respects with any provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations
promulgated in connection therewith, including Section 402 related to loans and Sections 302 and 906 related to certifications. 
 5.
Further Agreements of the Company and the Guarantors. The Company and the Guarantors jointly and severally covenant and agree with each Initial Purchaser that: 

(a) Delivery of Copies. The Company will deliver, without charge, to the Initial Purchasers as many copies of the Preliminary Offering
Memorandum, any other Time of Sale Information, any Issuer Written Communication and the Offering Memorandum (including all amendments and supplements thereto) as the Representatives may reasonably request. 

(b) Offering Memorandum, Amendments or Supplements. Before finalizing the Offering Memorandum or making or distributing any amendment or
supplement to any of the Time of Sale Information or the Offering Memorandum or filing with the Commission any document that will be incorporated by reference therein, the Company will furnish to the Representatives and counsel for the Initial
Purchasers a copy of the proposed Offering Memorandum or such amendment or supplement or document to be incorporated by reference therein for review, and will not distribute any such proposed Offering Memorandum, amendment or supplement or file any
such document with the Commission to which the Representatives reasonably object; provided, however, that the Representatives shall not object to any such filing if the Company obtains an opinion of outside counsel reasonably
satisfactory to the Representatives that such filing is required under the rules and regulations of the Securities Act or Exchange Act; provided, further, that the Company shall have the right to file with the Commission any report
required to be filed by the Company under the Exchange Act (based on the advice of the Company’s internal or external counsel) no later than the time period required by the Exchange Act. 

(c) Additional Written Communications. Before making, preparing, using, authorizing, approving or referring to any Issuer Written
Communication, the Company will furnish to the Representatives and counsel for the Initial Purchasers a copy of such written communication for review and will not make, prepare, use, authorize, approve or refer to any such written communication to
which the Representatives reasonably object. 
 (d) Notice to the Representatives. During the period beginning the date hereof and
ending on the latest of the Closing Date and the completion of the initial resale of the Securities by the Initial Purchasers, the Company will advise the Representatives promptly, and confirm such advice in writing, (i) of the issuance by any
governmental or regulatory authority of any order preventing or suspending the use of any of the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum or the 

  
 19 

 
initiation or threatening of any proceeding for that purpose; (ii) of the occurrence of any event at any time prior to the completion of the initial offering of the Securities as a result of
which any of the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances existing when such Time of Sale Information, Issuer Written Communication or the Offering Memorandum is delivered to a purchaser, not misleading; and (iii) of the receipt by the Company
of any notice with respect to any suspension of the qualification of the Securities for offer and sale in any jurisdiction or the initiation or threatening of any proceeding for such purpose; and the Company will use its reasonable best efforts to
prevent the issuance of any such order preventing or suspending the use of any of the Time of Sale Information, any Issuer Written Communication or the Offering Memorandum or suspending any such qualification of the Securities and, if any such order
is issued, will obtain as soon as possible the withdrawal thereof. 
 (e) Time of Sale Information. If at any time prior to the
Closing Date (i) any event shall occur or condition shall exist as a result of which any of the Time of Sale Information as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading or (ii) it is necessary to amend or supplement the Time of Sale Information to comply with law, the Company will
promptly notify the Initial Purchasers thereof and forthwith prepare and, subject to paragraph (b) of this Section 5, furnish to the Initial Purchasers such amendments or supplements to the Time of Sale Information (or any document to be
filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in any of the Time of Sale Information as so amended or supplemented (including such documents to be incorporated by reference therein) will
not, in the light of the circumstances under which they were made, be misleading or so that any of the Time of Sale Information will comply with law. 

(f) Ongoing Compliance. During the period beginning the date hereof and ending on the latest of the Closing Date and the completion of
the initial resale of the Securities by the Initial Purchasers, if at any time prior to the completion of the initial offering of the Securities (i) any event shall occur or condition shall exist as a result of which the Offering Memorandum as
then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Offering Memorandum is
delivered to a purchaser, not misleading or (ii) it is necessary to amend or supplement the Offering Memorandum to comply with law, the Company will promptly notify the Initial Purchasers thereof and forthwith prepare and, subject to paragraph
(b) of this Section 5, furnish to the Initial Purchasers such amendments or supplements to the Offering Memorandum (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the
statements in the Offering Memorandum as so amended or supplemented (including such document to be incorporated by reference therein) will not, in the light of the circumstances existing when the Offering Memorandum is delivered to a purchaser, be
misleading or so that the Offering Memorandum will comply with law. 

  
 20 

 (g) Blue Sky Compliance. The Company will qualify the Securities for offer and sale
under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for the offering and resale of the Securities by the Initial Purchasers;
provided that neither the Company nor any of the Guarantors shall be required to (i) qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so
qualify, (ii) file any general consent to service of process in any such jurisdiction or (iii) subject itself to taxation in any such jurisdiction if it is not otherwise so subject. 

(h) Clear Market. During the period from the date hereof through and including the date that is 60 days after the date hereof, the
Company and each of the Guarantors will not, without the prior written consent of J.P. Morgan Securities LLC, offer, sell, contract to sell or otherwise dispose of any debt securities issued or guaranteed by the Company or any of the Guarantors, as
applicable, and having a term of more than one year. 
 (i) Use of Proceeds. The Company will apply the net proceeds from the sale of
the Securities as described in each of the Time of Sale Information and the Offering Memorandum under the heading “Use of proceeds.” 

(j) Supplying Information. While the Securities remain outstanding and are “restricted securities” within the meaning of Rule
144(a)(3) under the Securities Act, the Company and each of the Guarantors will, during any period in which the Company is not subject to and in compliance with Section 13 or 15(d) of the Exchange Act, furnish to holders of the Securities and
prospective purchasers of the Securities designated by such holders, upon the request of such holders or such prospective purchasers, the information required to be delivered pursuant to Rule 144A(d)(4) under the Securities Act. 

(k) DTC. The Company will assist the Initial Purchasers in arranging for the Securities to be eligible for clearance and settlement
through DTC. 
 (l) No Integration. None of the Company or any of its affiliates (as defined in Rule 501(b) of Regulation D) will,
directly or through any agent, sell, offer for sale, solicit offers to buy or otherwise negotiate in respect of, any security (as defined in the Securities Act), that is or will be integrated with the sale of the Securities in a manner that would
require registration of the Securities under the Securities Act. 
 (m) No General Solicitation or Directed Selling Efforts. None of
the Company or any of its affiliates or any other person acting on its or their behalf (other than the Initial Purchasers, and persons acting on their behalf, as to which no covenant is given) will (i) solicit offers for, or offer or sell, the
Securities by means of any form of general solicitation or general advertising within the meaning of Rule 502(c) of Regulation D or in any manner involving a public offering within the meaning of Section 4(a)(2) of the Securities Act or
(ii) engage in any directed selling efforts within the meaning of Regulation S, and all such persons will comply with the offering restrictions requirement of Regulation S. 

  
 21 

 (n) No Stabilization. Neither the Company nor any of the Guarantors will take,
directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the Securities. 

(o) Perfection of Security Interests. The Company and each Guarantor shall complete on or prior to the Closing Date or such later date
permitted by the Collateral Documents, all filings and other actions required to be completed by them in connection with the perfection of first-priority liens and security interests in the Collateral as and to the extent required contemplated by
the Indenture and the Security Agreement, in each case as and to the extent contemplated by the Indenture and the Collateral Documents; provided that the Company and the Guarantors may deliver, satisfy and/or cause to be satisfied all of the
obligations set forth on Schedule 4 hereto within the time periods set forth therein. 
 (p) Filings, Registrations and Recordings. On
the Closing Date, subject to the matters contemplated by the Indenture, the Collateral Documents and Schedule 4 hereto, each document (including any Uniform Commercial Code financing statement) required by the Indenture or the Security Agreement, to
be filed, registered or recorded, or delivered by the Company or any Guarantor for filing on or prior to the Closing Date, including filings in the U.S. Patent and Trademark Office and the U.S. Copyright Office, in order to create in favor of the
Collateral Agent, for the benefit of itself, the Trustee and the holders of the Securities, a perfected first-priority lien and security interest in the personal property Collateral that can be perfected by the making of such filings, registrations
or recordation, prior and superior to the right of any other person (other than Permitted Liens), shall be executed and in proper form for filing, registration or recordation. 

6. Certain Agreements of the Initial Purchasers. Each Initial Purchaser hereby represents and agrees, severally and not jointly, that it
has not and will not use, authorize use of, refer to, or participate in the planning for use of, any written communication that constitutes an offer to sell or the solicitation of an offer to buy the Securities other than (i) the Preliminary
Offering Memorandum and the Offering Memorandum, (ii) any written communication that contains either (a) no “issuer information” (as defined in Rule 433(h)(2) under the Securities Act) or (b) “issuer information” that
was included (including through incorporation by reference) in the Time of Sale Information or the Offering Memorandum, (iii) any written communication listed on Annex A or prepared pursuant to Section 5(c) of this Agreement (including any
electronic road show), (iv) any written communication prepared by such Initial Purchaser and approved by the Company and the Representatives in advance in writing or (v) any written communication relating to or that contains the terms of the
Securities and/or other information that was included (including through incorporation by reference) in the Time of Sale Information or the Offering Memorandum. 

7. Conditions of Initial Purchasers’ Obligations. The obligation of each Initial Purchaser to purchase Securities on the Closing
Date as provided herein is subject to the performance by the Company and each of the Guarantors of their respective covenants and other obligations hereunder and to the following additional conditions: 

  
 22 

 (a) Representations and Warranties. The representations and warranties of the Company
and the Guarantors contained herein shall be true and correct on the date hereof and on and as of the Closing Date; and the statements of the Company, the Guarantors and their respective officers made in any certificates delivered pursuant to this
Agreement shall be true and correct on and as of the Closing Date. 
 (b) No Downgrade. Subsequent to the earlier of (A) the Time
of Sale and (B) the execution and delivery of this Agreement, (i) no downgrading shall have occurred in the rating accorded the Securities or any other debt securities or preferred stock issued or guaranteed by the Company or any of its
subsidiaries by any “nationally recognized statistical rating organization,” as such term is defined under Section 3(a)(62) under the Exchange Act and (ii) no such organization shall have publicly announced that it has under
surveillance or review, or has changed its outlook with respect to, its rating of the Securities or of any other debt securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries (other than an announcement with
positive implications of a possible upgrading). 
 (c) No Material Adverse Change. No event or condition of a type described in
Section 4(e) of this Agreement shall have occurred or shall exist, which event or condition is not described in each of the Time of Sale Information (excluding any amendment or supplement thereto) and the Offering Memorandum (excluding any
amendment or supplement thereto) the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the terms and in the manner contemplated by this
Agreement, the Time of Sale Information and the Offering Memorandum. 
 (d) Officer’s Certificate. The Representatives shall have
received on and as of the Closing Date a certificate of the chief financial officer or chief accounting officer of the Company on behalf of the Company (and not in his or her individual capacity) and of each Guarantor who has specific knowledge of
the Company’s or such Guarantor’s financial matters and is satisfactory to the Representatives (i) confirming that such officer has carefully reviewed the Time of Sale Information and the Offering Memorandum and, to the knowledge of
such officer, the representations set forth in Sections 4(a) and 4(b) of this Agreement are true and correct, (ii) confirming that the other representations and warranties of the Company and the Guarantors in this Agreement are (x) true
and correct (in the case of representations and warranties that are qualified with respect to materiality) or (y) are true and correct in all material respects (in the case of representation and warranties that are not so qualified) and that
the Company and the Guarantors have complied with all agreements and satisfied all conditions in all material respects on their part to be performed or satisfied hereunder at or prior to the Closing Date and (iii) to the effect set forth in
paragraphs (b) and (c) of this Section 7. 
 (e) Comfort Letters. On the date of this Agreement and on the Closing Date,
Ernst & Young LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Initial Purchasers, in form and substance reasonably satisfactory to
the Representatives, containing statements and information of the type customarily included in accountants’ “comfort letters” to underwriters with respect to the financial statements and certain financial information contained or
incorporated by reference in each of the Time of Sale Information and the Offering Memorandum; provided that the letter delivered on the Closing Date shall use a “cut-off” date no more than
three business days prior to the Closing Date. 

  
 23 

 (f) Opinion and 10b-5 Statement of Counsel for
the Company. Wilson Sonsini Goodrich & Rosati, Professional Corporation, counsel for the Company and the Guarantors, shall have furnished to the Representatives, at the request of the Company, their written opinion and 10b-5 statement, dated the Closing Date and addressed to the Initial Purchasers, in form and substance reasonably satisfactory to the Representatives, to the effect set forth in Annex D hereto. 

(g) Opinion and 10b-5 Statement of Counsel for the Initial Purchasers. The Representatives shall
have received on and as of the Closing Date an opinion and 10b-5 statement, addressed to the Initial Purchasers, of Simpson Thacher & Bartlett LLP, counsel for the Initial Purchasers, with respect to
such matters as the Representatives may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters. 

(h) No Legal Impediment to Issuance. No action shall have been taken and no statute, rule, regulation or order shall have been enacted,
adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Securities or the issuance of the Guarantees; and no injunction or order of any federal,
state or foreign court shall have been issued that would, as of the Closing Date, prevent the issuance or sale of the Securities or the issuance of the Guarantees. 

(i) Good Standing. The Representatives shall have received on and as of the Closing Date satisfactory evidence of the good standing of
the Company, the Guarantors and certain of their respective subsidiaries in their respective jurisdictions of organization and their good standing in such other jurisdictions as the Representatives may reasonably request, in each case in writing or
any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. 
 (j) DTC. The Securities
shall be eligible for clearance and settlement through DTC. 
 (k) Indenture and Securities. The Indenture shall have been duly
executed and delivered by a duly authorized officer of the Company, each of the Guarantors, the Trustee and the Collateral Agent, and the Securities shall have been duly executed and delivered by a duly authorized officer of the Company and duly
authenticated by the Trustee. 
 (l) Lien Searches. The Representatives shall have received the results of a recent lien search in
each of the jurisdictions where assets of the Company and the Guarantors are located and any jurisdictions in which valid filings with respect to such assets of the Company and the Guarantors may be in effect, and such search shall reveal no liens
on any of the assets of the Company and the Guarantors or their respective subsidiaries, except for Permitted Liens. 

  
 24 

 (m) Additional Documents. On or prior to the Closing Date, the Company and the
Guarantors shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. 

All opinions, letters, certificates and evidence mentioned in this Section 7 or elsewhere in this Agreement shall be deemed to be in
compliance with the provisions of this Agreement only if they are in form and substance reasonably satisfactory to counsel for the Initial Purchasers. 

8. Indemnification and Contribution. 

(a) Indemnification of the Initial Purchasers. The Company and each of the Guarantors jointly and severally agree to indemnify and hold
harmless each Initial Purchaser, its affiliates, directors and officers and each person, if any, who controls such Initial Purchaser within the meaning of Section 15 of the Securities Act or Section 20 of the Exchange Act, from and against
any and all losses, claims, damages and liabilities (including, without limitation, reasonable legal fees and other reasonable expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are
incurred), joint or several, that arise out of, or are based upon, any untrue statement or alleged untrue statement of a material fact contained in the Preliminary Offering Memorandum, any of the other Time of Sale Information, any Issuer Written
Communication, any road show as defined in Rule 433(h) under the Securities Act (a “road show”) or the Offering Memorandum (or any amendment or supplement thereto) or any omission or alleged omission to state therein a material fact
necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, in each case except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue
statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives
expressly for use therein, it being understood and agreed that the only such information furnished by any Initial Purchaser consists of the information described as such in Section 8(b) of this Agreement. 

(b) Indemnification of the Company and the Guarantors. Each Initial Purchaser agrees, severally and not jointly, to indemnify and hold
harmless the Company, each of the Guarantors, each of their respective directors and officers and each person, if any, who controls the Company or any of the Guarantors within the meaning of Section 15 of the Securities Act or Section 20
of the Exchange Act to the same extent as the indemnity set forth in paragraph (a) of this Section 8, but only with respect to any losses, claims, damages or liabilities (including, without limitation, reasonable legal fees and other
reasonable expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred) that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or
omission made in reliance upon and in conformity with any information relating to such Initial Purchaser furnished to the Company in writing by such Initial Purchaser through the Representatives expressly for use in the Preliminary Offering
Memorandum, any of the other Time of Sale Information, any Issuer Written Communication, any road show or the Offering Memorandum (or any amendment or supplement thereto), it being understood and 

  
 25 

 
agreed that the only such information consists of the following paragraphs in the Preliminary Offering Memorandum and the Offering Memorandum: the tenth paragraph under the heading “Plan of
distribution” (which, for the avoidance of doubt, begins with “In connection with the offering of the notes, the initial purchasers may engage in overallotment, stabilizing transactions and syndicate covering transactions”). 

(c) Notice and Procedures. If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand
shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to either paragraph (a) or (b) of this Section 8, such person (the “Indemnified Person”) shall promptly notify the
person against whom such indemnification may be sought (the “Indemnifying Person”) in writing; provided that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have under paragraph
(a) or (b) of this Section 8 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and provided, further, that the failure to notify the
Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under paragraph (a) or (b) of this Section 8. If any such proceeding shall be brought or asserted against an Indemnified
Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel to the
Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section 8 that the Indemnifying Person may designate in such proceeding and shall pay the fees and expenses of such proceeding
and shall pay the fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the
expense of such Indemnified Person unless (i) the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii) the Indemnifying Person has failed within a reasonable time to retain counsel reasonably
satisfactory to the Indemnified Person; (iii) the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those available to the Indemnifying Person; or
(iv) the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel would be inappropriate due to actual or
potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for the fees and expenses of more than one
separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Initial Purchaser, its affiliates, directors and
officers and any control persons of such Initial Purchaser shall be designated in writing by the Representatives and any such separate firm for the Company, the Guarantors, their respective directors and officers and any control persons of the
Company and the Guarantors shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent or if there be a final
judgment for the plaintiff, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or liability by reason of such settlement or judgment. 

  
 26 

 
Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as
contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i) such settlement is entered into more than 30 days after receipt by the Indemnifying Person
of such request and (ii) the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified
Person, effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement
(x) includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y) does not
include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. 
 (d)
Contribution. If the indemnification provided for in paragraph (a) or (b) of this Section 8 is unavailable to an Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then
each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities
(i) in such proportion as is appropriate to reflect the relative benefits received by the Company and the Guarantors on the one hand and the Initial Purchasers on the other from the offering of the Securities or (ii) if the allocation
provided by clause (i) is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits referred to in clause (i) but also the relative fault of the Company and the Guarantors on the one
hand and the Initial Purchasers on the other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable considerations. The relative benefits received by the
Company and the Guarantors on the one hand and the Initial Purchasers on the other shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses) received by the Company from the sale of the Securities and
the total discounts and commissions received by the Initial Purchasers in connection therewith, as provided in this Agreement, bear to the aggregate offering price of the Securities. The relative fault of the Company and the Guarantors on the one
hand and the Initial Purchasers on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to
information supplied by the Company or any Guarantor or by the Initial Purchasers and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission. 

(e) Limitation on Liability. The Company, the Guarantors and the Initial Purchasers agree that it would not be just and equitable if
contribution pursuant to this Section 8 were determined by pro rata allocation (even if the Initial Purchasers were treated as one entity for such purpose) or by any other method of allocation that does not take account of the
equitable considerations referred to in paragraph (d) of this Section 8. The amount paid or payable by an Indemnified Person as a result of the losses, claims, 

  
 27 

 
damages and liabilities referred to in paragraph (d) of this Section 8 shall be deemed to include, subject to the limitations set forth above, any legal or other expenses incurred by
such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of this Section 8, in no event shall an Initial Purchaser be required to contribute any amount in excess of the amount by which the total
discounts and commissions received by such Initial Purchaser with respect to the offering of the Securities exceeds the amount of any damages that such Initial Purchaser has otherwise been required to pay by reason of such untrue or alleged untrue
statement or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent
misrepresentation. The Initial Purchasers’ obligations to contribute pursuant to this Section 8 are several in proportion to their respective purchase obligations hereunder and not joint. 

(f) Non-Exclusive Remedies. The remedies provided for in this Section 8 are not exclusive
and shall not limit any rights or remedies that may otherwise be available to any Indemnified Person at law or in equity. 
 9.
Effectiveness of Agreement. This Agreement shall become effective as of the date first written above. 
 10. Termination. This
Agreement may be terminated in the absolute discretion of the Representatives, by notice to the Company, if after the execution and delivery of this Agreement and on or prior to the Closing Date (i) trading generally shall have been suspended
or materially limited on the New York Stock Exchange or the over-the-counter market; (ii) trading of any securities issued or guaranteed by the Company or any of
the Guarantors shall have been suspended on any exchange or in any over-the-counter market; (iii) a general moratorium on commercial banking activities shall have
been declared by federal or New York State authorities; or (iv) there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or crisis, either within or outside the United States, that,
in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Securities on the terms and in the manner contemplated by this Agreement, the Time of
Sale Information and the Offering Memorandum. 
 11. Defaulting Initial Purchaser. 

(a) If, on the Closing Date, any Initial Purchaser defaults on its obligation to purchase the Securities that it has agreed to purchase
hereunder, the non-defaulting Initial Purchasers may in their discretion arrange for the purchase of such Securities by other persons satisfactory to the Company on the terms contained in this Agreement. If,
within 36 hours after any such default by any Initial Purchaser, the non-defaulting Initial Purchasers do not arrange for the purchase of such Securities, then the Company shall be entitled to a further period
of 36 hours within which to procure other persons satisfactory to the non-defaulting Initial Purchasers to purchase such Securities on such terms. If other persons become obligated or agree to purchase the
Securities of a defaulting Initial Purchaser, either the non-defaulting Initial Purchasers or the Company may postpone the Closing Date for up 

  
 28 

 
to five full business days in order to effect any changes that in the opinion of counsel for the Company or counsel for the Initial Purchasers may be necessary in the Time of Sale Information,
the Offering Memorandum or in any other document or arrangement, and the Company agrees to promptly prepare any amendment or supplement to the Time of Sale Information or the Offering Memorandum that effects any such changes. As used in this
Agreement, the term “Initial Purchaser” includes, for all purposes of this Agreement unless the context otherwise requires, any person not listed in Schedule 1 hereto that, pursuant to this Section 11, purchases Securities that a
defaulting Initial Purchaser agreed but failed to purchase. 
 (b) If, after giving effect to any arrangements for the purchase of the
Securities of a defaulting Initial Purchaser or Initial Purchasers by the non-defaulting Initial Purchasers and the Company as provided in paragraph (a) of this Section 11, the aggregate principal
amount of such Securities that remains unpurchased does not exceed one-eleventh of the aggregate principal amount of all the Securities, then the Company shall have the right to require each non-defaulting Initial Purchaser to purchase the principal amount of Securities that such Initial Purchaser agreed to purchase hereunder plus such Initial Purchaser’s pro rata share (based on the
principal amount of Securities that such Initial Purchaser agreed to purchase hereunder) of the Securities of such defaulting Initial Purchaser or Initial Purchasers for which such arrangements have not been made. 

(c) If, after giving effect to any arrangements for the purchase of the Securities of a defaulting Initial Purchaser or Initial Purchasers by
the non-defaulting Initial Purchasers and the Company as provided in paragraph (a) of this Section 11, the aggregate principal amount of such Securities that remains unpurchased exceeds one-eleventh of the aggregate principal amount of all the Securities, or if the Company shall not exercise the right described in paragraph (b) of this Section 11, then this Agreement shall terminate
without liability on the part of the non-defaulting Initial Purchasers. Any termination of this Agreement pursuant to this Section 11 shall be without liability on the part of the Company or the
Guarantors, except that the Company and each of the Guarantors will continue to be liable for the payment of expenses as set forth in Section 12 of this Agreement and except that the provisions of Section 8 of this Agreement shall not
terminate and shall remain in effect. 
 (d) Nothing contained herein shall relieve a defaulting Initial Purchaser of any liability it may
have to the Company, the Guarantors or any non-defaulting Initial Purchaser for damages caused by its default. 

12. Payment of Expenses. 

(a) Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company and each of the
Guarantors jointly and severally agree to pay or cause to be paid all costs and expenses incident to the performance of their respective obligations hereunder, including without limitation, (i) the costs incident to the authorization, issuance,
sale, preparation and delivery of the Securities and any taxes payable in that connection; (ii) the costs incident to the preparation and printing of the Preliminary Offering Memorandum, any other Time of Sale Information, any Issuer Written
Communication and the Offering Memorandum (including any 

  
 29 

 
amendment or supplement thereto) and the distribution thereof; (iii) the costs of reproducing and distributing each of the Transaction Documents; (iv) the fees and expenses of the
Company’s and the Guarantors’ counsel and independent accountants; (v) the fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Securities under the
laws of such jurisdictions as the Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum (including the related fees and expenses of counsel for the Initial Purchasers); (vi) any fees charged by
rating agencies for rating the Securities; (vii) the fees and expenses of the Trustee, the Collateral Agent and any paying agent (including related fees and expenses of any counsel to such parties); (viii) all expenses and application fees
incurred in connection with the approval of the Securities for book-entry transfer by DTC; (ix) the fees and expenses incurred with respect to creating, documenting and perfecting the security interests in the Collateral as contemplated by the
Collateral Documents (including the related fees and expenses of counsel to the Initial Purchasers for all periods prior to and after the Closing Date); and (x) all expenses incurred by the Company in connection with any “road show”
presentation to potential investors. Except as provided in Section 8 and this Section 12, the Initial Purchasers shall pay all of their own costs and expenses in connection with the transactions contemplated hereby, including, without
limitation, the fees and expenses of their counsel. 
 (b) If (i) this Agreement is terminated pursuant to Section 10, (ii) the
Company for any reason fails to tender the Securities for delivery to the Initial Purchasers or (iii) the Initial Purchasers decline to purchase the Securities for any reason permitted under this Agreement, the Company and each of the
Guarantors jointly and severally agree to reimburse the Initial Purchasers for all out-of-pocket costs and expenses (including the fees and expenses of their counsel)
reasonably incurred by the Initial Purchasers in connection with this Agreement and the offering contemplated hereby. 
 13. Persons Entitled to Benefit
of Agreement. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Initial
Purchaser referred to in Section 8 hereof. Nothing in this Agreement is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained
herein. No purchaser of Securities from any Initial Purchaser shall be deemed to be a successor merely by reason of such purchase. 
 14.
Survival. The respective indemnities, rights of contribution, representations, warranties and agreements of the Company, the Guarantors and the Initial Purchasers contained in this Agreement or made by or on behalf of the Company, the
Guarantors or the Initial Purchasers pursuant to this Agreement or any certificate delivered pursuant hereto shall survive the delivery of and payment for the Securities and shall remain in full force and effect, regardless of any termination of
this Agreement or any investigation made by or on behalf of the Company, the Guarantors or the Initial Purchasers. 

  
 30 

 15. Certain Defined Terms. For purposes of this Agreement, (a) except where
otherwise expressly provided, the term “affiliate” has the meaning set forth in Rule 405 under the Securities Act; (b) the term “business day” means any day other than a day on which banks are permitted or
required to be closed in New York City; (c) the term “subsidiary” has the meaning set forth in Rule 405 under the Securities Act; (d) the term “Exchange Act” means the Securities Exchange Act of 1934, as
amended, and the rules and regulations of the Commission thereunder; and (e) the term “written communication” has the meaning set forth in Rule 405 under the Securities Act. 

16. Compliance with USA Patriot Act. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October 26, 2001)), the Initial Purchasers are required to obtain, verify and record information that identifies their respective clients, including the Company, which information may
include the name and address of their respective clients, as well as other information that will allow the Initial Purchasers to properly identify their respective clients. 

17. Miscellaneous. 
 (a)
Authority of the Representatives. Any action by the Initial Purchasers hereunder may be taken by the Representatives on behalf of the Initial Purchasers, and any such action taken by the Representatives shall be binding upon the Initial
Purchasers. 
 (b) Notices. All notices and other communications hereunder shall be in writing and shall be deemed to have been duly
given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Initial Purchasers shall be given to the Representatives c/o J.P. Morgan Securities LLC, 383 Madison Avenue, New York, New York 10179 (fax: (212) 270-1063), c/o Truist Securities, Inc. 3333 Peachtree Road NE, Atlanta, GA 30326; Attention: Investment Grade Debt Capital Markets, c/o Wells Fargo Securities, LLC, 550 South Tryon Street, 5th Floor, Charlotte,
North Carolina 28202 (email: tmgcapitalmarkets@wellsfargo.com; Attention: Transaction Management). Notices to the Company and the Guarantors shall be given to them at 2355 W. Chandler Blvd., Chandler, Arizona 85224 (fax: (480) 899-9210); Attention: Chief Financial Officer. 
 (c) Governing Law. This Agreement and any claim,
controversy or dispute arising under or related to this Agreement shall be governed by, and construed in accordance with, the laws of the State of New York. 

(d) Submission to Jurisdiction. The Company and each of the Guarantors hereby submit to the exclusive jurisdiction of the U.S. federal
and New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company and each of the Guarantors waive any objection
which it may now or hereafter have to the laying of venue of any such suit or proceeding in such courts. Each of the Company and each of the Guarantors agrees that final judgment in any such suit, action or proceeding brought in such court shall be
conclusive and binding upon the Company and each Guarantor, as applicable, and may be enforced in any court to the jurisdiction of which Company and each Guarantor, as applicable, is subject by a suit upon such judgment. 

  
 31 

 (e) Waiver of Jury Trial. Each of the parties hereto hereby waives any right to trial
by jury in any suit or proceeding arising out of or relating to this Agreement. 
 (f) Recognition of the U.S. Special Resolution
Regimes. 
 (i) In the event that any Initial Purchaser that is a Covered Entity becomes subject to a proceeding under a
U.S. Special Resolution Regime, the transfer from such Initial Purchaser of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special
Resolution Regime if this Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. 

(ii) In the event that any Initial Purchaser that is a Covered Entity or a BHC Act Affiliate of such Initial Purchaser becomes
subject to a proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Initial Purchaser are permitted to be exercised to no greater extent than such Default Rights could be exercised
under the U.S. Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. 

As used in this Section 16(f): 

“BHC Act Affiliate” has the meaning assigned to the term “affiliate” in, and shall be interpreted in accordance with, 12
U.S.C. § 1841(k). 
 “Covered Entity” means any of the following: 

(i) a “covered entity” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 252.82(b); 

(ii) a “covered bank” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 47.3(b); or 

(iii) a “covered FSI” as that term is defined in, and interpreted in accordance with, 12 C.F.R. § 382.2(b). 

“Default Right” has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R. §§ 252.81,
47.2 or 382.1, as applicable. 
 “U.S. Special Resolution Regime” means each of (i) the Federal Deposit Insurance Act and the
regulations promulgated thereunder and (ii) Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. 

  
 32 

 (g) Counterparts. This Agreement may be signed in counterparts (which may include
counterparts delivered by any standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. The words “execution,” “signed,” “signature,”
“delivery,” and words of like import in or relating to this Agreement or any document to be signed in connection with this Agreement shall be deemed to include electronic signatures, deliveries or the keeping of records in electronic form,
each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, and the parties hereto consent to conduct
the transactions contemplated hereunder by electronic means. 
 (h) Amendments or Waivers. No amendment or waiver of any provision of
this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. 

(i) Headings. The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the
meaning or interpretation of, this Agreement. 
  

  
 33 

 If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. 
  

			
	Very truly yours,
	
	MICROCHIP TECHNOLOGY INCORPORATED
		
	By	 	 /s/ J. Eric Bjornholt

	Name: J. Eric Bjornholt
	Title: Senior Vice President and Chief Financial Officer
	
	MICROCHIP HOLDING CORPORATION
		
	By	 	 /s/ J. Eric Bjornholt

	Name: J. Eric Bjornholt
	Title: Chief Financial Officer
	
	ATMEL CORPORATION
		
	By	 	 /s/ J. Eric Bjornholt

	Name: J. Eric Bjornholt
	Title: Vice President and Chief Financial Officer
	
	MICROSEMI CORPORATION
		
	By	 	 /s/ J. Eric Bjornholt

	Name: J. Eric Bjornholt
	Title: Chief Financial Officer

 Signature Page to Purchase Agreement 

  
 34 

 
			
	MICROSEMI STORAGE SOLUTIONS, INC.
		
	By	 	 /s/ J. Eric Bjornholt

	Name: J. Eric Bjornholt
	Title: Chief Financial Officer
	
	SILICON STORAGE TECHNOLOGY, INC.
		
	By	 	 s/ J. Eric Bjornholt

	Name: J. Eric Bjornholt
	Title: Chief Financial Officer
	
	MICROCHIP TECHNOLOGY LLC
	
	By: Microchip Technology Incorporated, its sole member
		
	By	 	 /s/ J. Eric Bjornholt

	Name: J. Eric Bjornholt
	Title: Senior Vice President and Chief Financial Officer

 Signature Page to Purchase Agreement 

  
 35 

			
	Accepted: As of the date first written above
	
	J.P. MORGAN SECURITIES LLC
	TRUIST SECURITIES, INC.
	WELLS FARGO SECURITIES, LLC
	For themselves and on behalf of the several
	Initial Purchasers listed in Schedule 1 hereto.
	
	J.P. MORGAN SECURITIES LLC
		
	By	 	 /s/ Som Bhattacharyya

		 	Authorized Signatory
	
	TRUIST SECURITIES, INC.
		
	By	 	 /s/ Rob Nordlinger

	      Authorized Signatory
	
	WELLS FARGO SECURITIES, LLC
		
	By	 	 /s/ Carolyn Hurley

	      Authorized Signatory

 Signature Page to Purchase Agreement 

  
 36 

 Schedule 1 
  

					
	 Initial Purchaser
	  	Principal Amount	 
	 J.P. Morgan Securities LLC
	  	$	400,000,000	 
	 Truist Securities, Inc.
	  	$	80,000,000	 
	 Wells Fargo Securities, LLC
	  	$	60,000,000	 
	 BNP Paribas Securities Corp.
	  	$	50,000,000	 
	 RBC Capital Markets, LLC
	  	$	45,000,000	 
	 Mizuho Securities USA LLC
	  	$	45,000,000	 
	 BofA Securities, Inc.
	  	$	40,000,000	 
	 BMO Capital Markets Corp.
	  	$	40,000,000	 
	 U.S. Bancorp Investments, Inc.
	  	$	40,000,000	 
	 MUFG Securities Americas Inc.
	  	$	40,000,000	 
	 Fifth Third Securities, Inc.
	  	$	40,000,000	 
	 DBS Bank Ltd.
	  	$	40,000,000	 
	 Scotia Capital (USA) Inc.
	  	$	40,000,000	 
	 TD Securities (USA) LLC
	  	$	40,000,000	 
	 Total
	  	$	1,000,000,000	 

  
 37 

 Schedule 2 

Guarantors 
 Atmel Corporation, a Delaware
corporation 
 Microchip Holding Corporation, a Delaware corporation 

Microchip Technology LLC, a Delaware limited liability company 

Microsemi Corporation, a Delaware corporation 
 Microsemi
Storage Solutions, Inc., a Delaware corporation 
 Silicon Storage Technology, Inc., a California corporation 

  
 38 

 Schedule 3 

Significant Subsidiaries 
 Atmel Corporation 

Jurisdiction: Delaware 
 Microchip Holding Corporation 

Jurisdiction: Delaware 
 Microchip Technology (Thailand) Co.,
Ltd. 
 Jurisdiction: Thailand 
 Microchip Technology
(Barbados) II Incorporated 
 Jurisdiction: Cayman Islands 

Microchip Technology Ireland Limited 
 Jurisdiction: Ireland 

Microchip Technology Malta Limited 
 Jurisdiction: Ireland 

  
 39 

 Schedule 4 

Certain Collateral Requirements 
  

	 	•	 	 The Company shall deliver to the Collateral Agent the share mortgage to be entered into in respect of certain
equity interests of Microchip Technology Malta Limited on the date required by the Collateral Documents. 

  
 40 

 ANNEX A 

Additional Time of Sale Information 

1. Term sheet containing the terms of the Securities, substantially in the form of Annex B. 

  
 A-1 

 ANNEX B 

Pricing Term Sheet 

Strictly Confidential 

Pricing Term Sheet, dated May 18, 2021 

to Preliminary Offering Memorandum dated May 18, 2021 

Microchip Technology Incorporated 

$1,000,000,000 0.983% Senior Secured Notes due 2024 

This pricing term sheet is qualified in its entirety by reference to the Preliminary Offering Memorandum, dated May 18, 2021 (the “Preliminary Offering
Memorandum”). The information in this pricing term sheet supplements the Preliminary Offering Memorandum and updates and supersedes the information in the Preliminary Offering Memorandum to the extent it is inconsistent with the information in
the Preliminary Offering Memorandum. Terms used and not defined herein have the meanings assigned in the Preliminary Offering Memorandum. 
  

			
	Issuer:	  	Microchip Technology Incorporated
		
	Security description:	  	0.983% Senior Secured Notes due 2024 (the “Secured Notes”)
		
	Principal amount:	  	$1,000,000,000
		
	Gross proceeds:	  	$1,000,000,000
		
	Maturity:	  	September 1, 2024
		
	Coupon:	  	0.983%
		
	Issue price:	  	100.000% of face amount
		
	Yield to maturity:	  	0.983%
		
	Spread to Benchmark Treasury:	  	+65 basis points
		
	Benchmark Treasury:	  	UST 0.250% due May 15, 2024
		
	Benchmark Treasury price and yield:	  	99-24 1⁄8+/0.333%
		
	Interest payment dates:	  	March 1 and September 1, commencing September 1, 2021
		
	Record dates:	  	February 15 and August 15

  
 B-1 

			
	Optional redemption:	  	Prior to the maturity date of the Secured Notes, the Issuer may, at its option, redeem the Secured Notes, in whole or in part, at a redemption price equal to the greater of 100% of the principal amount of the Secured Notes being
redeemed and the “make-whole” amount to the maturity date at a discount rate equal to the Treasury Rate plus 10 basis points, plus, in each case accrued and unpaid interest to, but excluding, the date of redemption.
		
	Change of control:	  	Upon the occurrence of a Change of Control Triggering Event, the Issuer must offer to repurchase the Secured Notes at a repurchase price in cash equal to 101% of the aggregate principal amount of the Secured Notes repurchased, plus
accrued and unpaid interest to, but excluding, the repurchase date.
		
	CUSIP / ISIN:	  	 144A: 595017AX2 / US595017AX27
 Reg S: U59332AF0
/ USU59332AF01

		
	Trade date:	  	May 18, 2021
		
	Settlement:	  	 T+8; May 28, 2021.
  

It is expected that delivery of the Secured Notes will be made against payment therefor on or about May 28, 2021, which is the eighth business day following
the date hereof (such settlement cycle being referred to as “T+8”). Under Rule 15c6-1 under the Exchange Act, trades in the secondary market generally are required to settle in two business days
unless the parties to any such trade expressly agree otherwise. Accordingly, purchasers who wish to trade the Secured Notes any date prior to the second business day before delivery thereof will be required, by virtue of the fact that the Secured
Notes initially will settle in T+8, to specify an alternative settlement cycle at the time of any such trade to prevent failed settlement. Purchasers of the Secured Notes who wish to trade the Secured Notes prior to the second business day preceding
their date of delivery hereunder should consult their own advisors.

		
	Use of proceeds:	  	The Issuer intends to use the net proceeds from this offering, together with borrowings under the Senior Credit Facilities, to repay the Issuer’s outstanding 3.922% Senior Secured Notes due 2021 (the “2021 Notes”) at
maturity and to pay accrued and unpaid interest on the 2021 Notes and all related fees and expenses of the offering.
		
	Distribution:	  	Rule 144A / Regulation S for life; no registration rights.
		
	Denominations/Multiple:	  	Denominations of $2,000 and any integral multiples of $1,000 in excess thereof
		
	Ratings*	  	Baa3 / BBB- (Moody’s/Fitch)
		
	Joint book-running managers:	  	 J.P. Morgan Securities LLC
 Truist Securities,
Inc.
 Wells Fargo Securities, LLC
 BNP Paribas Securities
Corp.

		
	Co-managers:	  	 RBC Capital Markets, LLC
 Mizuho Securities USA
LLC
 BofA Securities, Inc.
 BMO Capital Markets Corp.

U.S. Bancorp Investments, Inc.

  
 B-2 

			
		  	 MUFG Securities Americas Inc.
 Fifth Third
Securities, Inc.
 DBS Bank Ltd.
 Scotia Capital (USA) Inc.

TD Securities (USA) LLC

  
  

	*	 A securities rating is not a recommendation to buy, sell or hold securities and may be subject to revision or
withdrawal at any time. 

 This material is confidential and is for your information only and is not intended to be used by anyone
other than you. This information does not purport to be a complete description of these notes or the offering. Please refer to the Preliminary Offering Memorandum for a complete description. 

The Secured Notes have not been registered under the Securities Act of 1933, as amended (the “Securities Act”), or the securities laws of any
jurisdiction. Accordingly, the Secured Notes are being offered and sold only to, and this communication is being distributed solely to, (1) persons reasonably believed to be “qualified institutional buyers,” as defined in Rule
144A under the Securities Act, or (2) outside the United States to non-U.S. persons in compliance with Regulation S under the Securities Act. For further details about eligible offerees and resale
restrictions, see the section of the Preliminary Offering Memorandum captioned “Transfer restrictions.” 
 This communication does not
constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction to any person to whom it is unlawful to make such offer or solicitation in such jurisdiction. 

Any disclaimer or other notice that may appear below is not applicable to this communication and should be disregarded. Such disclaimer or notice was
automatically generated as a result of this communication being sent by Bloomberg or another email system. 

  
 B-3 

 ANNEX C 

Restrictions on Offers and Sales Outside the United States 

In connection with offers and sales of Securities outside the United States: 

(a) Each Initial Purchaser acknowledges that the Securities have not been registered under the Securities Act and may not be offered or sold
within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an exemption from, or in transactions not subject to, the registration requirements of the Securities Act. 

(b) Each Initial Purchaser, severally and not jointly, represents, warrants and agrees that: 

(i) Such Initial Purchaser has offered and sold the Securities, and will offer and sell the Securities, (A) as part of
their distribution at any time and (B) otherwise until 40 days after the later of the commencement of the offering of the Securities and the Closing Date, only in accordance with Regulation S under the Securities Act (“Regulation
S”) or Rule 144A or any other available exemption from registration under the Securities Act. 
 (ii) None of such
Initial Purchaser or any of its affiliates or any other person acting on its or their behalf has engaged or will engage in any directed selling efforts with respect to the Securities, and all such persons have complied and will comply with the
offering restrictions requirement of Regulation S. 
 (iii) At or prior to the confirmation of sale of any Securities sold in
reliance on Regulation S, such Initial Purchaser will have sent to each distributor, dealer or other person receiving a selling concession, fee or other remuneration that purchases Securities from it during the distribution compliance period a
confirmation or notice to substantially the following effect: 
 The Securities covered hereby have not been registered under the U.S.
Securities Act of 1933, as amended (the “Securities Act”), and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons (i) as part of their distribution at any time or
(ii) otherwise until 40 days after the later of the commencement of the offering of the Securities and the date of original issuance of the Securities, except in accordance with Regulation S or Rule 144A or any other available exemption from
registration under the Securities Act. Terms used above have the meanings given to them by Regulation S. 

  
 C-1 

 (iv) Such Initial Purchaser has not and will not enter into any contractual
arrangement with any distributor with respect to the distribution of the Securities, except with its affiliates or with the prior written consent of the Company. 

Terms used in paragraph (a) and this paragraph (b) and not otherwise defined in this Agreement have the meanings given to them by Regulation S. 

(c) Each Initial Purchaser acknowledges that no action has been or will be taken by the Company that would permit a public offering of the
Securities, or possession or distribution of any of the Time of Sale Information, the Offering Memorandum, any Issuer Written Communication or any other offering or publicity material relating to the Securities, in any country or jurisdiction where
action for that purpose is required. 

  
 C-2 

 ANNEX D 

Form of WSGR Opinion for the Company and the Guarantors 

Opinions to be included as set forth below: 
  

	 	1.	 Each of the Company, Atmel, MHC, Microsemi and Microsemi Storage has been duly incorporated and is validly
existing as a corporation in good standing under the laws of the State of Delaware. MT LLC is a limited liability company duly formed and validly existing under the laws of the State of Delaware and is in good standing under such laws. SST is a
corporation duly incorporated and validly existing under the laws of the State of California and is in good standing under such laws. The Company and each of the Subsidiary Guarantors have the corporate or limited liability company, as applicable,
power and authority to own its properties and to conduct its business as described in the Disclosure Package and the Final Offering Memorandum. 

  

	 	2.	 The Purchase Agreement has been duly authorized, executed and delivered by the Company and the Subsidiary
Guarantors. 

  

	 	3.	 The Notes are in the form contemplated by the Indenture and have been duly authorized by the Company; the
Notes, when executed by the Company and authenticated by the Trustee in accordance with the terms of the Indenture and delivered against the purchase price therefor specified in the Purchase Agreement in accordance with the terms of the Purchase
Agreement (which facts we have not determined by inspection of the Securities), will constitute valid and binding obligations of the Company and enforceable against the Company in accordance with their terms; and the Securities are entitled to the
benefits of the Indenture. 

  

	 	4.	 The Note Guarantees have been duly authorized, executed and delivered by the Subsidiary Guarantors and
constitute valid and binding instruments, enforceable against each Subsidiary Guarantor in accordance with their terms. 

  

	 	5.	 The Indenture has been duly authorized, executed and delivered by the Company and each Subsidiary Guarantor and
constitute valid and binding instruments, enforceable against the Company and each Subsidiary Guarantor in accordance with its terms. 

  

	 	6.	 The Security Documents have been duly authorized by the Company and each Subsidiary Guarantor that is a party
thereto and constitute valid and legally binding obligations, enforceable against the Company and each Subsidiary Guarantor party thereto in accordance with their respective terms. The Joinder has been duly authorized, executed and delivered by the
Company and each Subsidiary Guarantor and the Intercreditor Agreement, as supplemented by the Joinder, constitutes valid and legally binding obligations, enforceable against the Company and each Subsidiary Guarantor party thereto in accordance with
its terms. 

  
 D-1 

	 	7.	 None of the execution, delivery and performance of the Purchase Agreement, the Indenture, the Security
Documents or the Intercreditor Agreement, as supplemented by the Joinder, or the issuance and sale of the Notes or the Note Guarantees, or the consummation of any other of the transactions contemplated thereby will conflict with, result in a breach
or violation of any of the terms or provisions of, or constitute a default under (A) the Charter Documents, (B) (i) any statute, decree, regulation or order known to us to be applicable to the Company, Atmel, MHC, Microchip LLC, Microsemi
or Microsemi Storage of any U.S. federal, New York or Delaware court, governmental authority or agency having jurisdiction over the Company, Atmel, MHC, Microchip LLC, Microsemi or Microsemi Storage or any of their properties or assets and
(ii) any statute, decree, regulation or order known to us to be applicable to SST of any U.S. federal, New York or California court, governmental authority or agency having jurisdiction over SST or any of its properties or assets, (C) any
Reviewed Agreements or (D) any Reviewed Judgments. 

  

	 	8.	 No consent, approval, authorization, order, registration or qualification of or with any such court or
governmental agency or body is required for the issue and sale of the Securities or the consummation by the Company and each Subsidiary Guarantor of the transactions contemplated by the Purchase Agreement, the Indenture, the Security Agreement or
the Intercreditor Agreement, as supplemented by the Joinder, except as contemplated by the Indenture and the Securities and such consents, approvals, authorizations, registrations or qualifications as may be required under state securities or Blue
Sky laws in connection with the purchase and distribution of the Securities by the Initial Purchasers. 

  

	 	9.	 The Company is not and, immediately after giving effect to the offering and sale of the Securities and the
application of the net proceeds thereof, as described in the Final Offering Memorandum, will not be required to register as an “investment company,” as such term is defined in the Investment Company Act. 

 

	 	10.	 The statements set forth in the Disclosure Package and the Final Offering Memorandum under the caption
“Description of notes,” insofar as they purport to constitute a summary of the terms of the Securities, the Indenture, the Security Documents and the Intercreditor Agreement, fairly summarize such terms and documents in all material
respects. 

  

	 	11.	 The statements set forth in the Disclosure Package and the Final Offering Memorandum under the caption
“Certain U.S. federal income tax considerations,” insofar as they purport to summarize provisions of the United States federal tax laws or legal conclusions with respect thereto, fairly summarize such matters in all material respects.

  
 D-2 

	 	12.	 No registration of the Securities under the Act is required for the sale of the Securities by the Company and
the Subsidiary Guarantors to the Initial Purchasers pursuant to the Purchase Agreement or for the initial resale of the Securities by the Initial Purchasers in the manner contemplated by the Purchase Agreement, the Disclosure Package and the Final
Offering Memorandum, and it is not necessary to qualify the Indenture under the Trust Indenture Act (it being understood that, in each case, no opinion is expressed as to any subsequent resale of the Securities or the consequences thereof).

  

	 	13.	 The Security Agreement is sufficient to create a valid security interest in favor of the Securities Collateral
Agent in the collateral described therein to the extent a security interest in such collateral may be created under Article 9 of the New York UCC. 

  

	 	14.	 If a financing statement in the form of each Delaware Financing Statement is communicated to the Delaware
Secretary of State by an authorized method of communication and an amount equal to the applicable filing fee is tendered to such filing office, such filing office will have an obligation to accept such financing statement. Upon acceptance of a
Delaware Financing Statement by such filing office, the security interests in the collateral described in both such Delaware Financing Statement and the Security Agreement, and for which perfection under Article 9 of the Delaware UCC may occur by
the filing of a UCC-1 financing statement with the Delaware Secretary of State, will be perfected. 

  

	 	15.	 If a financing statement in the form of the California Financing Statement is communicated to the California
Secretary of State by an authorized method of communication and an amount equal to the applicable filing fee is tendered to such filing office, such filing office will have an obligation to accept such financing statement. Upon acceptance of the
California Financing Statement by such filing office, the security interest in the collateral described in both the California Financing Statement and the Security Agreement, and for which perfection under Division 9 of the California UCC may occur
by the filing of a UCC-1 financing statement with the California Secretary of State, will be perfected. 

  
 D-3 

 Form of WSGR 10b-5 Statement 

We have participated in conferences with certain officers and other representatives of the Company, representatives of the Initial Purchasers,
counsel for the Initial Purchasers and representatives of the independent certified public accountants of the Company at which the contents of the General Disclosure Package, the Final Offering Memorandum and related matters were reviewed and
discussed and, although we are not passing upon and do not assume any responsibility for the accuracy, completeness or fairness of the General Disclosure Package or the Final Offering Memorandum (except to the extent of our statements in paragraphs
10 and 11 of our opinion letter separately delivered to you today pursuant to the Purchase Agreement), and we have made no independent check or verification thereof, no facts have come to our attention in the course of such review and discussion
that have caused us to believe that: 
 (i) the General Disclosure Package, as of [•] p.m. New York time on May 18, 2021, contained
an untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading, or 

(ii) the Final Offering Memorandum, as of its date or as of the date hereof, contained or contains an untrue statement of a material fact or
omitted or omits to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading. 

In providing this letter to you as Initial Purchasers, we have not been called to pass upon, and we express no view regarding, the financial
statements and related schedules and the financial and statistical data based on or derived from such financial statements or schedules included in or omitted from the General Disclosure Package or Final Offering Memorandum. Further, we express no
view as to the conveyance of the General Disclosure Package or the information contained therein to investors. 

  
 D-4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00328-of-00352.parquet"}]]